

Primary chemotherapy versus primary surgery for new cancer (CHORUS): an open-label, randomised, controlled

Lancet, The

386, 249-257

DOI: [10.1016/s0140-6736\(14\)62223-6](https://doi.org/10.1016/s0140-6736(14)62223-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	2751 Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian, and primary peritoneal carcinomas. <i>European Journal of Cancer</i> , 2015, 51, S547.	1.3	0
2	Radiotherapy and locally advanced rectal cancer. <i>British Journal of Surgery</i> , 2015, 102, 1443-1445.	0.1	7
3	Frontline treatment of epithelial ovarian cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 1-16.	0.7	12
4	Association of Preoperative Thrombocytosis and Leukocytosis With Postoperative Morbidity and Mortality Among Patients With Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2015, 126, 1191-1197.	1.2	23
5	Neoadjuvant chemotherapy for ovarian cancer: do we have enough evidence?. <i>Lancet, The</i> , 2015, 386, 223-224.	6.3	22
6	Primary chemotherapy versus primary surgery for ovarian cancer. <i>Lancet, The</i> , 2015, 386, 2142.	6.3	2
7	Primary chemotherapy versus primary surgery for ovarian cancer. <i>Lancet, The</i> , 2015, 386, 2142-2143.	6.3	5
8	Primary chemotherapy versus primary surgery for ovarian cancer – Authors' reply. <i>Lancet, The</i> , 2015, 386, 2143.	6.3	10
9	BrÃves de lâ€™AERIO. <i>Oncologie</i> , 2015, 17, 595-598.	0.2	0
10	Screening for ovarian cancer. <i>Maturitas</i> , 2015, 81, 423-424.	1.0	2
11	Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. <i>Gynecologic Oncology</i> , 2015, 138, 757-761.	0.6	32
12	Global cancer surgery: delivering safe, affordable, and timely cancer surgery. <i>Lancet Oncology, The</i> , 2015, 16, 1193-1224.	5.1	442
13	Diagnosis of ovarian cancer. <i>BMJ, The</i> , 2015, 351, h4443.	3.0	68
14	High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation. <i>Cancer Letters</i> , 2015, 369, 363-367.	3.2	82
15	Bevacizumab in newly diagnosed ovarian cancer. <i>Lancet Oncology, The</i> , 2015, 16, 876-878.	5.1	8
16	Reduction of CA125 Levels During Neoadjuvant Chemotherapy Can Predict Cytorreduction to No Visible Residual Disease in Patients with Advanced Epithelial Ovarian Cancer, Primary Carcinoma of Fallopian tube and Peritoneal Carcinoma. <i>Journal of Cancer</i> , 2016, 7, 2327-2332.	1.2	28
17	Surgical treatment pattern and outcomes in epithelial ovarian cancer patients from a cancer institute in Kerala, India. <i>Ecancermedalscience</i> , 2016, 10, 619.	0.6	6
18	Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 143-151.	1.8	22

#	ARTICLE	IF	CITATIONS
19	Chemotherapy for ovarian cancer. <i>Journal of the Korean Medical Association</i> , 2016, 59, 175.	0.1	3
20	Major clinical research advances in gynecologic cancer in 2015. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e53.	1.0	20
21	Transvaginal Sonography-Guided Core Biopsy of Adnexal Masses as a Useful Diagnostic Alternative Replacing Cytologic Examination or Laparoscopy in Advanced Ovarian Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1041-1047.	1.2	6
22	SEOM Clinical Guideline in ovarian cancer (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1206-1212.	1.2	15
23	Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: Society of Gynecologic Oncology and ASCO Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2016, 12, 1254-1257.	2.5	5
24	Response to the letter of Fagotti et al. regarding the manuscript: "Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery". <i>Gynecologic Oncology Reports</i> , 2016, 18, 55-56.	0.3	1
25	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?. <i>Oncologist</i> , 2016, 21, 529-531.	1.9	3
26	Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 142, 25-29.	0.6	16
28	Advantage of Extended Craniofacial Resection for Advanced Malignant Tumors of the Nasal Cavity and Paranasal Sinuses: Long-Term Outcome and Surgical Management. <i>World Neurosurgery</i> , 2016, 89, 240-254.	0.7	16
29	What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?. <i>Annals of Surgical Oncology</i> , 2016, 23, 1666-1673.	0.7	43
30	Update on Imaging of Ovarian Cancer. <i>Current Radiology Reports</i> , 2016, 4, 31.	0.4	51
31	A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: A single-institution assessment. <i>Gynecologic Oncology</i> , 2016, 142, 19-24.	0.6	41
32	Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3854-3863.	0.8	112
33	Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. <i>Clinical Oncology</i> , 2016, 28, 760-765.	0.6	7
34	Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 143, 496-503.	0.6	12
35	Downregulation of Notch Signaling Pathway as an Effective Chemosensitizer for Cancer Treatment. <i>Drug Research</i> , 2016, 66, 571-579.	0.7	34
36	How to Select Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients With Stage IIIC or IV Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3827-3828.	0.8	35
37	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. <i>Gynecologic Oncology</i> , 2016, 142, 458-464.	0.6	17

#	ARTICLE	IF	CITATIONS
38	Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature. <i>Oncology</i> , 2016, 91, 211-216.	0.9	10
39	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3460-3473.	0.8	318
40	Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Gynecologic Oncology</i> , 2016, 143, 3-15.	0.6	208
41	Interval Laparoscopic En-Bloc Resection of the Pelvis (L-EnBRP) in patients with stage IIIc-IV ovarian cancer: Description of the technique and surgical outcomes. <i>Gynecologic Oncology</i> , 2016, 142, 477-483.	0.6	13
42	Handbook of Consult and Inpatient Gynecology. , 2016, , .		1
43	Improving outcomes for older women with gynaecological malignancies. <i>Cancer Treatment Reviews</i> , 2016, 50, 99-108.	3.4	39
44	Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. <i>Gynecologic Oncology</i> , 2016, 143, 236-240.	0.6	97
45	Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients. <i>Journal of Oncology Practice</i> , 2016, 12, 666-673.	2.5	14
46	Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1283-1288.	1.1	12
47	The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 899-901.	1.1	10
48	Cytotoxic and targeted therapy for hereditary cancers. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 17.	0.6	37
49	Ovarian cancer. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16061.	18.1	761
50	Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis. <i>Scientific Reports</i> , 2016, 6, 35914.	1.6	14
51	Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy. <i>ESMO Open</i> , 2016, 1, esmoopen-2016-000117.	2.0	5
52	Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. <i>Journal of Ovarian Research</i> , 2016, 9, 85.	1.3	10
54	Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIc and IV epithelial ovarian cancer. <i>Medicine (United States)</i> , 2016, 95, e4797.	0.4	34
55	Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 607-614.	0.8	27
56	Neoadjuvant chemotherapy in ovarian cancer revisited. <i>Annals of Oncology</i> , 2016, 27, i30-i32.	0.6	11

#	ARTICLE	IF	CITATIONS
57	Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. <i>European Journal of Cancer</i> , 2016, 64, 22-31.	1.3	180
58	Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3025-3036.	3.2	124
59	FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. <i>Gynecologic Oncology</i> , 2016, 142, 597-607.	0.6	64
61	Population-level scale-up of surgery platforms for women's cancer care in low- and middle-income countries. <i>Journal of Cancer Policy</i> , 2016, 7, 23-27.	0.6	2
62	Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 140, 436-442.	0.6	97
63	Can advanced-stage ovarian cancer be cured?. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 255-261.	12.5	292
64	Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma: a glimmer of hope in select patients. <i>Archives of Gynecology and Obstetrics</i> , 2016, 293, 47-53.	0.8	24
65	Nintedanib and ovarian cancer: standardise surgery in trials?. <i>Lancet Oncology</i> , The, 2016, 17, 9-11.	5.1	4
66	Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: An external validation study of three models using computed tomography. <i>Gynecologic Oncology</i> , 2016, 140, 22-28.	0.6	21
67	Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. <i>Gynecologic Oncology</i> , 2016, 141, 264-270.	0.6	46
68	Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer. <i>Oncologist</i> , 2016, 21, 745-754.	1.9	56
69	Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. <i>European Journal of Cancer</i> , 2016, 59, 22-33.	1.3	297
70	Prise en charge chirurgicale des cancers de l'ovaire à un stade avancé: synthèse. <i>Medecine Nucleaire</i> , 2016, 40, 248-250.	0.2	0
71	Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. <i>Gynecologic Oncology</i> , 2016, 140, 425-429.	0.6	10
72	Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1509-1520.	1.2	20
73	Ovarian cancer: is chemotherapy before surgery the way forward?. <i>International Journal of Endocrine Oncology</i> , 2016, 3, 5-12.	0.4	1
74	Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 1.	1.3	20
75	Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial "NCT02324595"): a feasibility study. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 503.e1-503.e6.	0.7	66

#	ARTICLE	IF	CITATIONS
76	Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report. <i>BMC Cancer</i> , 2017, 17, 26.	1.1	14
77	Neoadjuvant Chemotherapy or Primary Debulking Surgery for Stage IIIC Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 802-803.	0.8	6
78	Internationally Comparable Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. <i>Clinical Oncology</i> , 2017, 29, 151-152.	0.6	0
79	Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2017, 20, 131.	0.3	1
80	Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit. <i>Gynecologic Oncology</i> , 2017, 144, 468-473.	0.6	28
81	Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. <i>Gynecologic Oncology</i> , 2017, 145, 21-26.	0.6	58
82	Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. <i>Journal of Clinical Oncology</i> , 2017, 35, 587-590.	0.8	38
83	<i>ABC2</i> , an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells. <i>Molecular Carcinogenesis</i> , 2017, 56, 1543-1553.	1.3	76
84	Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 613-621.	0.8	103
85	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. <i>Gynecologic Oncology</i> , 2017, 145, 15-20.	0.6	55
86	Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). <i>Cancer</i> , 2017, 123, 977-984.	2.0	31
87	Worldwide Abortion Rates and Access to Contraception. <i>Obstetrics and Gynecology</i> , 2017, 129, 783-785.	1.2	1
88	Committee Opinion No. 704: Human Papillomavirus Vaccination. <i>Obstetrics and Gynecology</i> , 2017, 129, e173-e178.	1.2	45
89	Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy. <i>Obstetrics and Gynecology</i> , 2017, 129, 861-869.	1.2	55
90	The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 696-702.	1.2	16
91	British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 213, 123-139.	0.5	64
92	Utilizing <i>Salmonella</i> to treat solid malignancies. <i>Journal of Surgical Oncology</i> , 2017, 116, 75-82.	0.8	7
93	Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. <i>Annals of Oncology</i> , 2017, 28, 711-717.	0.6	125

#	ARTICLE	IF	CITATIONS
94	Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 52-57.	0.6	12
95	Ovarian cancer stem cells more questions than answers. <i>Seminars in Cancer Biology</i> , 2017, 44, 67-71.	4.3	128
96	A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 668-674.	1.2	42
97	Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 708-713.	1.2	38
98	Trends in Mortality After Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized Clinical Trials and Observational Studies. <i>Annals of Surgical Oncology</i> , 2017, 24, 1688-1697.	0.7	29
99	Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. <i>European Journal of Cancer</i> , 2017, 70, 133-142.	1.3	86
100	Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, 76.	3.4	77
101	Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent?. <i>Current Opinion in Oncology</i> , 2017, 29, 351-358.	1.1	8
102	Ovarian Cancer and Comorbidity: Is Poor Survival Explained by Choice of Primary Treatment or System Delay?. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1123-1133.	1.2	12
103	Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 320-328.	0.8	11
104	Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 28-36.	1.2	31
105	Management of advanced ovarian cancer in South West Wales â a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort. <i>Cancer Epidemiology</i> , 2017, 49, 85-91.	0.8	2
106	Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers. <i>Cancer Letters</i> , 2017, 397, 127-132.	3.2	28
107	Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival. <i>Gynecologic Oncology</i> , 2017, 145, 500-507.	0.6	18
108	Maternal Cardiovascular Mortality in Illinois, 2002â2011. <i>Obstetrics and Gynecology</i> , 2017, 129, 819-826.	1.2	61
109	Comparison of Vaginal Hysterectomy Techniques and Interventions for Benign Indications. <i>Obstetrics and Gynecology</i> , 2017, 129, 877-886.	1.2	20
110	Successful Continuation of Pregnancy After Treatment of Group A Streptococci Sepsis. <i>Obstetrics and Gynecology</i> , 2017, 129, 907-910.	1.2	1
111	Trends in Maternal Mortality by Sociodemographic Characteristics and Cause of Death in 27 States and the District of Columbia. <i>Obstetrics and Gynecology</i> , 2017, 129, 811-818.	1.2	108

#	ARTICLE	IF	CITATIONS
112	Emerging Infectious Diseases in Pregnancy. <i>Obstetrics and Gynecology</i> , 2017, 129, 896-906.	1.2	30
113	Effect of a pH-Balanced Vaginal Gel on Dyspareunia and Sexual Function in Breast Cancer Survivors Who Were Premenopausal at Diagnosis. <i>Obstetrics and Gynecology</i> , 2017, 129, 870-876.	1.2	9
114	What Is New in Amniotic Fluid Embolism?. <i>Obstetrics and Gynecology</i> , 2017, 129, 941-942.	1.2	1
115	Geographic Variance of Cost Associated With Hysterectomy. <i>Obstetrics and Gynecology</i> , 2017, 129, 844-853.	1.2	13
116	The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up. <i>Gynecologic Oncology Reports</i> , 2017, 20, 47-50.	0.3	8
117	Comparison of survival outcome of patients with primary peritoneal and fallopian tube carcinoma treated with neoadjuvant chemotherapy versus primary debulking surgery. <i>Journal of Obstetrics and Gynaecology</i> , 2017, 37, 89-92.	0.4	6
118	Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Position Statement. <i>Maturitas</i> , 2017, 100, 86-91.	1.0	16
119	The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 451-458.	0.8	32
120	Image-guided nanomedicine for cancer. <i>Journal of Pharmaceutical Investigation</i> , 2017, 47, 51-64.	2.7	19
121	The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 681-687.	0.8	11
122	Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?. <i>Gynecologic Oncology</i> , 2017, 144, 238-240.	0.6	6
123	Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 144, 474-479.	0.6	25
124	Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. <i>Gynecologic Oncology</i> , 2017, 144, 266-273.	0.6	38
125	Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. <i>Gynecologic Oncology</i> , 2017, 144, 256-259.	0.6	38
126	The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1850-1855.	1.2	5
127	Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?. <i>Gynecologic Oncology</i> , 2017, 147, 607-611.	0.6	17
128	The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIc-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1856-1862.	1.2	42
130	Ovarian Cancer Therapy by <i>VSVMP</i> Gene Mediated by a Paclitaxel-Enhanced Nanoparticle. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 39152-39164.	4.0	13

#	ARTICLE	IF	CITATIONS
131	Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 219, 100-105.	0.5	16
132	Associations between residual disease and survival in epithelial ovarian cancer by histologic type. <i>Gynecologic Oncology</i> , 2017, 147, 250-256.	0.6	33
133	The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 441-442.	0.6	0
134	FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. <i>Gynecologic Oncology</i> , 2017, 147, 3-10.	0.6	36
135	Barriers to Primary Debulking Surgery for Advanced Ovarian Cancer in Latin America. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1645-1649.	1.2	7
136	Research in Gynaecological Oncology. , 0, , 255-259.		0
137	Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian, fallopian tube and/or primary peritoneal cancer. <i>The Cochrane Library</i> , 0, , .	1.5	1
138	Is there a revision needed of the current <scp>FIGO</scp> staging system?. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2017, 96, 1159-1161.	1.3	4
139	The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2017, 57, 651-658.	0.4	16
140	Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer Ascites. <i>Molecular Therapy - Oncolytics</i> , 2017, 6, 31-44.	2.0	12
141	Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2017, 37, 1070-1075.	0.4	7
142	Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1610-1618.	1.2	8
143	The evolving role of cytopathology in the era of neoadjuvant chemotherapy for the accurate pathologic diagnosis of epithelial ovarian cancer. <i>Cancer Cytopathology</i> , 2017, 125, 743-744.	1.4	1
144	Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1863-1871.	1.2	44
145	Total Infragastric Omentectomy Including the Vascular Perigastric Arcade in Patients With Advanced Serous Ovarian Tumors. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 252-257.	1.2	4
146	Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer—A National Cancer Database Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 675-683.	1.2	19
147	Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers. <i>Annals of Surgical Oncology</i> , 2017, 24, 3396-3405.	0.7	11
148	Poor Prognostic Factors in Patients Undergoing Surgery After Neoadjuvant Chemotherapy for Ovarian, Tubal, or Peritoneal Cancer. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 1163-1170.	0.3	6

#	ARTICLE	IF	CITATIONS
149	Survival and safety associated with aggressive surgery for stage III/IV epithelial ovarian cancer: A single institution observation study. <i>Gynecologic Oncology</i> , 2017, 147, 73-80.	0.6	19
150	PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1095-1103.	0.8	99
151	Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 912-920.	0.4	13
152	Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 449-456.	0.6	15
153	VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients. <i>Future Oncology</i> , 2017, 13, 409-414.	1.1	5
155	Surgery for advanced epithelial ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 71-87.	1.4	32
156	Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 126-138.	1.4	32
157	Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 1019-1023.	0.6	8
158	Neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Who really benefits?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2017, 57, 585-587.	0.4	3
159	Clinical Significance of Nodal Positivity Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 1.	0.1	0
160	Real-world evidence in the treatment of ovarian cancer. <i>Annals of Oncology</i> , 2017, 28, viii61-viii65.	0.6	211
161	Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. <i>Annals of Oncology</i> , 2017, 28, 702-710.	0.6	46
162	Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. <i>F1000Research</i> , 2017, 6, 84.	0.8	16
163	Neoadjuvant, adjuvant and long-term intravenous/intraperitoneal chemotherapy, hyperthermic intraperitoneal chemotherapy, early postoperative intraperitoneal chemotherapy for ovarian cancer. <i>Journal of Peritoneum (and Other Serosal Surfaces)</i> , 2017, , .	0.1	1
164	External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e73.	1.0	58
165	Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e45.	1.0	24
166	The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 172-179.	0.9	33
167	Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach. <i>Cancer Management and Research</i> , 2017, Volume 9, 869-878.	0.9	9

#	ARTICLE	IF	CITATIONS
168	Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2539-2551.	1.0	45
169	Timing of Cytoreductive Surgery in the Treatment of Advanced Epithelial Ovarian Carcinoma. , 2017, , 59-78.		0
170	Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome. <i>PLoS ONE</i> , 2017, 12, e0186725.	1.1	41
171	Prediction model for 30-day morbidity after gynecological malignancy surgery. <i>PLoS ONE</i> , 2017, 12, e0178610.	1.1	6
172	1st Evidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer. <i>Tumori</i> , 2017, 103, 525-536.	0.6	11
173	Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer. <i>Journal of Nippon Medical School</i> , 2017, 84, 170-176.	0.3	8
174	Extra-peritoneal hysteroansectomy with eventual concomitant en bloc rectal resection and cytoreductive surgery in epithelial ovarian cancer (and other peritoneal surface malignancies): technical details. <i>Journal of Peritoneum (and Other Serosal Surfaces)</i> , 2017, , .	0.1	0
175	Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e48.	1.0	25
176	Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3471-3479.	2.0	12
177	The Effect of CA125 Nadir Level on Survival of Advanced-Stage Epithelial Ovarian Carcinoma after Interval Debulking Surgery. <i>Journal of Cancer</i> , 2017, 8, 3410-3415.	1.2	11
178	Reply to M.S. Copur et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 803-803.	0.8	0
179	The Tip of the Iceberg. <i>Journal of Clinical Oncology</i> , 2017, 35, 801-802.	0.8	1
180	Molybdenum cluster loaded PLGA nanoparticles: An innovative theranostic approach for the treatment of ovarian cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 125, 95-105.	2.0	55
181	Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 847-851.	1.1	2
182	Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 149, 447-454.	0.6	16
183	Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 223, 98-102.	0.5	4
184	Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection. <i>Gynecologic Oncology</i> , 2018, 149, 256-262.	0.6	6
185	A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2018, 44, 1294-1301.	0.6	7

#	ARTICLE	IF	CITATIONS
186	Representation of obese participants in obesity-related cancer randomized trials. <i>Annals of Oncology</i> , 2018, 29, 1582-1587.	0.6	20
187	Examining Survival Outcomes of 852 Women With Advanced Ovarian Cancer: A Multi-institutional Cohort Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 925-931.	1.2	21
188	The role of neoadjuvant chemotherapy in ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 555-566.	1.1	34
189	Role of laparoscopy in initial tumour staging in advanced epithelial ovarian cancer: a systematic review. <i>Pleura and Peritoneum</i> , 2018, 3, 20180106.	0.5	11
190	Radiological and Surgical Correlation of Disease Burden in Advanced Ovarian Cancer Using Peritoneal Carcinomatosis Index. <i>Indian Journal of Gynecologic Oncology</i> , 2018, 16, 1.	0.1	5
191	Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis. <i>Gynecologic and Obstetric Investigation</i> , 2018, 83, 209-219.	0.7	11
192	Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 760-765.	0.5	46
193	Examining the Selection Criteria of Neoadjuvant Chemotherapy Patients. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, 595-603.	0.3	1
194	A Vesicular Stomatitis Virus-Inspired DNA Nanocomplex for Ovarian Cancer Therapy. <i>Advanced Science</i> , 2018, 5, 1700263.	5.6	16
195	Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase. <i>Gynecologic Oncology</i> , 2018, 148, 329-335.	0.6	14
196	Top 10 Tips Palliative Care Clinicians Should Know When Caring for Patients with Ovarian Cancer. <i>Journal of Palliative Medicine</i> , 2018, 21, 250-254.	0.6	5
197	Frontline therapy of ovarian cancer: trials and tribulations. <i>Current Opinion in Obstetrics and Gynecology</i> , 2018, 30, 1-6.	0.9	7
198	A multidisciplinary approach to oncology trials: Study conduct of the ANTHALYA trial. <i>Contemporary Clinical Trials</i> , 2018, 65, 151-156.	0.8	0
199	OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 431-438.	0.6	54
200	Tips and Tricks in Advanced Stage Ovarian Cancer (AOC) Surgery. <i>Indian Journal of Gynecologic Oncology</i> , 2018, 16, 1.	0.1	0
201	HIPEC in patients with primary advanced ovarian cancer: Is there a role? A systematic review of short- and long-term outcomes. <i>Surgical Oncology</i> , 2018, 27, 251-258.	0.8	15
202	Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. <i>BMJ: British Medical Journal</i> , 2018, 360, j5463.	2.4	27
203	Ovarian Cancer Surgery in Australia and New Zealand: A Survey to Determine Changes in Surgical Practice Over 10 Years. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 945-950.	1.2	10

#	ARTICLE	IF	CITATIONS
204	Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 55-63.	1.1	4
205	A Prediction Model and Risk Calculator for Surgical Mortality and Serious Morbidity After Primary Cytoreductive Surgery. <i>Journal of Gynecologic Surgery</i> , 2018, 34, 1-5.	0.0	1
206	Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status. <i>International Journal of Clinical Oncology</i> , 2018, 23, 698-706.	1.0	7
207	Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications. <i>Gynecologic Oncology</i> , 2018, 149, 263-269.	0.6	35
209	Epithelial Ovarian Cancer. , 2018, , 253-289.e14.		3
210	Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer. <i>Journal of Robotic Surgery</i> , 2018, 12, 245-250.	1.0	13
211	Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. <i>Journal of Surgical Oncology</i> , 2018, 117, 488-496.	0.8	15
212	National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 19-25.	1.2	20
213	The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma. <i>Histopathology</i> , 2018, 72, 619-625.	1.6	35
214	No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. <i>European Journal of Cancer</i> , 2018, 88, 31-37.	1.3	92
215	Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 148, 62-67.	0.6	30
216	Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications. <i>International Journal of Cancer</i> , 2018, 143, 8-15.	2.3	28
217	Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 148, 168-173.	0.6	14
218	Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery. <i>Gynecologic Oncology</i> , 2018, 148, 56-61.	0.6	18
219	Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety. <i>Annals of Surgical Oncology</i> , 2018, 25, 247-254.	0.7	10
220	Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1676-1682.	1.2	18
221	Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e56.	1.0	20
222	Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e63.	1.0	12

#	ARTICLE	IF	CITATIONS
223	Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e47.	1.0	39
224	ATL. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1498-1506.	1.2	15
225	Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced Ovarian Cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1520-1528.	1.2	18
226	Operation. , 2018, , .		0
227	Treatment Decisions and Survival in Ovarian Cancer. , 0, , .		0
228	Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer. <i>The Cochrane Library</i> , 2018, 2018, CD012567.	1.5	19
229	Surgical Management of Ovarian Cancer. , 2018, , .		0
230	Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application. , 0, , .		1
231	Patient Selection for Ovarian Cancer Debulking Surgery. , 0, , .		0
232	Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. <i>Lancet Oncology</i> , The, 2018, 19, 1680-1687.	5.1	187
233	Diagnosis and Treatment of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 943-964.	0.9	185
234	Neoadjuvant chemotherapy versus upfront debulking surgery in advanced tubo-ovarian cancer. <i>Lancet Oncology</i> , The, 2018, 19, 1558-1560.	5.1	11
235	Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals. <i>Radiology and Oncology</i> , 2018, 52, 307-319.	0.6	40
237	Prognostic implications of histological tumor regression (BÅrhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma. <i>Gynecologic Oncology</i> , 2018, 151, 264-268.	0.6	28
238	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 59-78.	1.0	205
239	Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery. <i>BMC Cancer</i> , 2018, 18, 1041.	1.1	3
240	Artemisinin derivatives inhibit epithelial ovarian cancer cells via autophagy-mediated cell cycle arrest. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 1227-1235.	0.9	34
241	Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 414-421.	0.6	36

#	ARTICLE	IF	CITATIONS
242	Epidermal growth factor receptor blockers for the treatment of ovarian cancer. The Cochrane Library, 2018, 2018, CD007927.	1.5	16
243	Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIICâ€“IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study. International Journal of Gynecological Cancer, 2018, 28, 1706-1713.	1.2	4
244	Complications and Management of Radical Cytoreduction. , 2018, , 182-191.		0
245	Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer. Obstetrics and Gynecology Science, 2018, 61, 227.	0.6	21
246	Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: A feasibility study. Journal of Surgical Oncology, 2018, 118, 687-693.	0.8	8
247	Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy. PLoS ONE, 2018, 13, e0203366.	1.1	8
248	Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network. Oncology Reports, 2018, 40, 2659-2673.	1.2	26
249	Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience. Yonsei Medical Journal, 2018, 59, 930.	0.9	6
250	Surgical and Medical Management of Epithelial Ovarian Cancer. , 2018, , 884-904.		0
251	Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstetrics and Gynecology, 2018, 132, 545-554.	1.2	49
252	The Unyielding Fight Against the Premature Death of Patients With Advanced-Stage Ovarian Cancer. Obstetrics and Gynecology, 2018, 132, 541-544.	1.2	2
253	Clinical Management of Epithelial Ovarian Cancer. , 2018, , 135-151.		0
254	Dioscin suppresses the viability of ovarian cancer cells by regulating the VEGFR2 and PI3K/AKT/MAPK signaling pathways. Oncology Letters, 2018, 15, 9537-9542.	0.8	24
255	Diaphragm disease in advanced ovarian cancer: Predictability of pre-operative imaging and safety of surgical intervention. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 226, 47-53.	0.5	13
256	Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States. Cancer Epidemiology, 2018, 55, 8-16.	0.8	5
257	Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecologic Oncology, 2018, 150, 451-459.	0.6	33
258	Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival. Gynecologic Oncology, 2018, 150, 306-310.	0.6	16
259	A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience. Journal of Ovarian Research, 2018, 11, 42.	1.3	21

#	ARTICLE	IF	CITATIONS
260	Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer. <i>European Journal of Pharmacology</i> , 2018, 837, 64-71.	1.7	3
261	Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?. <i>Cancers</i> , 2018, 10, 241.	1.7	55
262	A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e65.	1.0	27
263	Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 150, 19-22.	0.6	14
264	The limits of aggressive surgical cytoreduction. <i>Gynecologic Oncology</i> , 2018, 150, 205-206.	0.6	1
265	Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 150, 446-450.	0.6	42
266	Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients. <i>Journal of Obstetrics and Gynaecology Research</i> , 2018, 44, 1808-1816.	0.6	7
267	Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review. <i>Gynecologic Oncology</i> , 2018, 150, 370-377.	0.6	14
268	The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies. <i>Oncotarget</i> , 2018, 9, 8614-8628.	0.8	31
269	Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1077-1084.	1.2	12
271	Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model. <i>Gynecologic Oncology</i> , 2018, 151, 129-133.	0.6	2
272	Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?. <i>Gynecologic Oncology</i> , 2018, 151, 24-31.	0.6	64
273	Surgery in ovarian cancer – Brazilian Society of Surgical Oncology consensus. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 1243-1252.	1.1	3
274	Cytoreductive Surgery and Intraperitoneal Chemotherapy for Advanced Epithelial Ovarian Cancer. , 2018, , 221-252.		0
275	Neoadjuvant Chemotherapy Treatment Modifications in Ovarian Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 17-20.	0.6	3
276	Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). <i>International Journal of Gynecological Pathology</i> , 2019, 38, 230-240.	0.9	33
277	Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer. <i>Tumori</i> , 2019, 105, 92-97.	0.6	28
278	Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis. <i>Journal of Robotic Surgery</i> , 2019, 13, 23-33.	1.0	25

#	ARTICLE	IF	CITATIONS
279	Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 585-592.	1.2	16
280	Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2416-2419.	0.8	17
281	Hypoxic Isolated Abdominal Perfusion (HAP) chemotherapy for non-operable advanced staged ovarian cancer with peritoneal carcinosis: an experience in 45 platinum-refractory ovarian cancer patients. <i>Indian Journal of Surgical Oncology</i> , 2019, 10, 506-514.	0.3	5
282	Socioeconomic differences impact overall survival in advanced ovarian cancer (AOC) prior to achievement of standard therapy. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 1261-1270.	0.8	7
283	Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 58-62.	0.6	31
284	Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2398-2405.	0.8	28
285	Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study. <i>Journal of Surgical Oncology</i> , 2019, 120, 786-793.	0.8	4
287	Aggressive surgery for advanced ovarian cancer performed by a multidisciplinary team: A retrospective analysis on a large series of patients. <i>Surgery Open Science</i> , 2019, 1, 43-47.	0.5	12
288	Morbidity of multiple bowel resection compared to single bowel resection after debulking surgery for ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 240, 215-219.	0.5	10
289	Ovarian High-Grade Serous Carcinoma. <i>Surgical Pathology Clinics</i> , 2019, 12, 515-528.	0.7	7
290	Quality of life outcomes following surgery for advanced ovarian cancer: a systematic review and meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1285-1291.	1.2	10
291	A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 326.e1-326.e7.	0.7	21
292	Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer. <i>Journal of Surgical Oncology</i> , 2019, 120, 779-785.	0.8	7
293	Fallopian Tube Carcinoma. <i>Journal of Oncology Practice</i> , 2019, 15, 375-382.	2.5	28
294	Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery. <i>Healthcare (Switzerland)</i> , 2019, 7, 85.	1.0	8
295	The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e91.	1.0	5
296	A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy. <i>Gynecologic Oncology</i> , 2019, 154, 622-630.	0.6	35
297	Overall survival is the primary endpoint in a trial of neoadjuvant chemotherapy for bladder cancer?. <i>Cancer</i> , 2019, 125, 4105-4106.	2.0	2

#	ARTICLE	IF	CITATIONS
298	Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic high-grade serous carcinoma. <i>Cancer Medicine</i> , 2019, 8, 4598-4604.	1.3	6
299	Measuring response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response score. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 929-934.	1.2	11
300	Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1050-1056.	1.2	39
301	Trends in the overall survival rates in women with advanced ovarian cancer in a single tertiary centre in New Zealand. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2019, 59, 861-866.	0.4	0
302	Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment. <i>International Journal of Pharmaceutics</i> , 2019, 571, 118751.	2.6	25
303	Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC. <i>Journal of Surgical Oncology</i> , 2019, 120, 1208-1219.	0.8	13
304	Review of the Outcomes of Ovarian Cancer Treated with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy. <i>Indian Journal of Gynecologic Oncology</i> , 2019, 17, 1.	0.1	0
305	MiR-506-3p suppresses the proliferation of ovarian cancer cells by negatively regulating the expression of MTMR6. <i>Journal of Biosciences</i> , 2019, 44, 1.	0.5	22
306	Prevention of Anastomotic Leakage in Ovarian Cancer Debulking Surgery and Its Impact on Overall Survival. <i>Anticancer Research</i> , 2019, 39, 5209-5218.	0.5	20
307	Surgical recommendations in the era of personalized medicine: What can we learn from patient preferences?. <i>Cancer</i> , 2019, 125, 4367-4370.	2.0	0
308	Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer. <i>Cancer</i> , 2019, 125, 4399-4406.	2.0	16
309	Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study. <i>Radiation Oncology</i> , 2019, 14, 179.	1.2	11
310	Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1156-1163.	1.2	4
311	TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR) Tj ETQq1 1.0.784314 rgBT /Ov	1.2	108
312	Hopes and failures in front-line ovarian cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 14-19.	2.0	51
313	<p>Feasibility and safety of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in patients with advanced stage ovarian cancer: a single-center experience</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6931-6940.	0.9	7
314	Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs. <i>JAMA Network Open</i> , 2019, 2, e199570.	2.8	13
315	Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 240, 364-369.	0.5	7

#	ARTICLE	IF	CITATIONS
316	Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease. <i>Frontiers in Oncology</i> , 2019, 9, 778.	1.3	33
317	Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: An Institutional Experience. <i>Indian Journal of Gynecologic Oncology</i> , 2019, 17, 1.	0.1	0
318	State of the science: Evolving role of surgery for the treatment of ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 3-7.	0.6	7
319	Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model. <i>PLoS ONE</i> , 2019, 14, e0222828.	1.1	0
320	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2403-2415.	13.9	627
321	Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC). <i>Cells</i> , 2019, 8, 1186.	1.8	10
322	Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?. <i>Gynecologic Oncology</i> , 2019, 155, 192-200.	0.6	14
323	Neoadjuvant therapy in gynaecological malignancies: What pathologists need to know. <i>Journal of Clinical Pathology</i> , 2019, 72, 102-111.	1.0	2
324	Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: A meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 64-69.	2.0	15
325	Ovarian Cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 67-88.	0.7	12
327	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. <i>Gynecologic Oncology</i> , 2019, 154, 441-448.	0.6	74
328	Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2019, 154, 283-289.	0.6	19
329	Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. <i>Gynecologic Oncology</i> , 2019, 154, 77-82.	0.6	24
330	New Approaches to Improving Survival After Neoadjuvant Chemotherapy: The Role of Intraperitoneal Therapy and Heated Intraperitoneal Chemotherapy in Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, , 19-23.	1.8	1
331	Interpreting Randomized Clinical Trials in Gynecologic Oncology Surgery: Does One Size Fit All?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 342-350.	1.8	5
332	A Role for NF- κ B in Organ Specific Cancer and Cancer Stem Cells. <i>Cancers</i> , 2019, 11, 655.	1.7	84
333	Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 392-397.	1.2	4
334	Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1064-1071.	1.2	2

#	ARTICLE	IF	CITATIONS
335	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 280-304.	157.7	821
336	ESMOâ€“ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>Annals of Oncology</i> , 2019, 30, 672-705.	0.6	665
337	ESMOâ€“ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 728-760.	1.2	167
338	Neoadjuvant Chemotherapy Followed by Surgery for Advanced-Stage Endometrial Cancer. <i>Current Oncology</i> , 2019, 26, 226-232.	0.9	30
339	RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 237, 93-99.	0.5	14
340	Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708). <i>BMC Cancer</i> , 2019, 19, 341.	1.1	12
341	Neoadjuvant chemotherapy in patients with advanced endometrial cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 281-285.	1.1	32
342	Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1425-1431.	0.5	8
343	Measuring cause-and-effect relationships without randomized clinical trials: Quasi-experimental methods for gynecologic oncology research. <i>Gynecologic Oncology</i> , 2019, 152, 533-539.	0.6	16
344	The American College of Surgeon's surgical risk calculator's ability to predict disposition in older gynecologic oncology patients undergoing laparotomy. <i>Journal of Geriatric Oncology</i> , 2019, 10, 618-622.	0.5	8
345	Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIâ€“IV ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e25.	1.0	19
346	Role of discoidin domain receptor 2 (DDR2) and microRNA-182 in survival of women with high-grade serous ovarian cancer. <i>Tumor Biology</i> , 2019, 41, 101042831882398.	0.8	11
347	High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. <i>International Journal of Molecular Sciences</i> , 2019, 20, 952.	1.8	381
348	Adnexal mass staging CT with a disease-specific structured report compared to simple structured report. <i>European Radiology</i> , 2019, 29, 4851-4860.	2.3	7
349	The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review. <i>Gynecologic Oncology</i> , 2019, 153, 445-451.	0.6	22
350	Epithelial ovarian cancer. <i>Lancet, The</i> , 2019, 393, 1240-1253.	6.3	1,039
351	Mucinous Ovarian Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1256-1266.	13.9	143
353	Peritonectomy and hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer: What gynaecological oncologists really think. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2019, 59, 457-462.	0.4	6

#	ARTICLE	IF	CITATIONS
354	Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. <i>Gynecologic Oncology</i> , 2019, 152, 501-508.	0.6	16
355	Multifactorial impact on the outcome of interval debulking surgery in patients with advanced epithelial ovarian or peritoneal cancers. <i>Clinica Chimica Acta</i> , 2019, 495, 148-153.	0.5	1
357	Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 571.e1-571.e8.	0.7	29
358	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. <i>Endocrine Connections</i> , 2019, 8, R10-R26.	0.8	33
359	Gynecological Cancers—the Changing Paradigm. <i>Indian Journal of Surgical Oncology</i> , 2019, 10, 156-161.	0.3	0
360	Evaluation of Computed Tomography Scan and CA 125 Response in Predicting Operability in Advanced Ovarian Cancer and Assessing Survival Outcome in Interval Cytoreductive Surgery. <i>Indian Journal of Surgical Oncology</i> , 2019, 10, 426-434.	0.3	2
361	First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1095-1103.	1.0	53
363	A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. <i>New England Journal of Medicine</i> , 2019, 380, 822-832.	13.9	373
365	Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on. <i>Cancer</i> , 2019, 125, 4587-4593.	2.0	25
366	Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 11497-11506.	1.0	21
367	Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1341-1347.	1.2	27
368	Dilution of Molecular Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 213-219.	3.2	12
369	Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. <i>The Cochrane Library</i> , 2019, 2019, .	1.5	34
370	Quality Indicators and Survival Outcome in Stage IIIB-IVB Epithelial Ovarian Cancer Treated at a Single Institution. <i>In Vivo</i> , 2019, 33, 1521-1530.	0.6	11
371	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIg phase 3 randomised controlled trial. <i>Lancet</i> , 2019, 394, 2084-2095.	6.3	142
372	Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior. <i>Scientific Reports</i> , 2019, 9, 17996.	1.6	24
373	Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer. <i>The Cochrane Library</i> , 2019, 2019, CD009786.	1.5	32
374	Biomarkers in ovarian cancer: To be or not to be. <i>Cancer</i> , 2019, 125, 4563-4572.	2.0	38

#	ARTICLE	IF	CITATIONS
375	The Feasibility of Cardiophrenic Lymphnode Assessment and Removal in Patients Requiring Diaphragmatic Resection During Interval Debulking Surgery for Ovarian Cancer. <i>Journal of Investigative Surgery</i> , 2021, 34, 756-762.	0.6	11
376	Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage III B vs stage IV epithelial ovarian cancer after primary surgery. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 34-43.	1.3	20
377	Neoadjuvant chemotherapy in high-risk ovarian cancer patients: Role of age. <i>Tumori</i> , 2019, 105, 168-173.	0.6	7
378	Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2019, 152, 554-559.	0.6	14
379	GEN-1 immunotherapy for the treatment of ovarian cancer. <i>Future Oncology</i> , 2019, 15, 421-438.	1.1	11
380	Ovarian cancer stem cells: What progress have we made?. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 107, 92-103.	1.2	41
381	Validation of a peritoneal surface disease severity score in stage III C-IV ovarian cancer treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. <i>Surgical Oncology</i> , 2019, 28, 57-61.	0.8	6
382	Impact of Laparoscopy to Assess Resectability in Stage III C Epithelial Ovarian, Tubal and Peritoneal Cancer Patients. <i>Gynecologic and Obstetric Investigation</i> , 2019, 84, 259-267.	0.7	3
383	Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands. <i>BMC Cancer</i> , 2019, 19, 58.	1.1	19
384	CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2019, 152, 568-573.	0.6	7
385	Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e3.	1.0	25
386	The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 5-9.	1.2	54
387	Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer. <i>Cancer Medicine</i> , 2019, 8, 564-571.	1.3	10
388	Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review. <i>Indian Journal of Gynecologic Oncology</i> , 2019, 17, 1.	0.1	0
389	Ovarian cancer in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27512.	0.8	17
390	Does Neoadjuvant Chemotherapy Impact Prognosis in Advanced-Stage Epithelial Ovarian Cancer Optimally Debulked at Surgery?. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 185-190.	0.3	4
391	Practice patterns of surgery for advanced ovarian cancer: analysis from international surveys. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 137-145.	0.6	21
392	When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 902-909.	0.3	26

#	ARTICLE	IF	CITATIONS
393	Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer. <i>Journal of Surgical Research</i> , 2020, 246, 34-41.	0.8	15
394	Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer. <i>Abdominal Radiology</i> , 2020, 45, 828-841.	1.0	2
395	Carcinoma of the Ovaries and Fallopian Tubes. , 2020, , 1525-1543.e7.		0
396	An update on preoperative assessment of the resectability of advanced ovarian cancer. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.3	2
397	Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 142, 105136.	1.9	69
398	Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 502-507.	1.0	9
399	Fast Single Image Dehazing Using Saturation Based Transmission Map Estimation. <i>IEEE Transactions on Image Processing</i> , 2020, 29, 1985-1998.	6.0	60
400	Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy. <i>International Journal of Cancer</i> , 2020, 146, 1851-1861.	2.3	19
401	A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer. <i>Journal of Visceral Surgery</i> , 2020, 157, 79-86.	0.4	7
402	A TGF- β 2 associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 233-242.	0.6	5
403	Compliance to treatment guidelines and survival in women undergoing interval debulking surgery for advanced epithelial ovarian cancer. <i>Cancer Reports</i> , 2020, 3, e1217.	0.6	1
405	A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 9-10.	3.2	1
406	Prediction of Epithelial Ovarian Cancer Outcomes With Integration of Genomic Data. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 92-108.	0.6	6
407	Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: A French national multicenter study (FRANCOGYN). <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 245, 64-72.	0.5	13
408	Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2020, 46, 868-875.	0.5	24
409	A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 206-213.	2.1	13
410	Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram. <i>Frontiers in Oncology</i> , 2020, 10, 560888.	1.3	4
411	Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1657-1664.	1.2	220

#	ARTICLE	IF	CITATIONS
412	Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e12.	1.0	12
413	New approaches for targeting platinum-resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021, 77, 167-181.	4.3	38
414	The accuracy of ascites cytology in diagnosis of advanced ovarian cancer in postmenopausal women prior to neoadjuvant chemotherapy. <i>Menopause</i> , 2020, 27, 771-775.	0.8	8
415	Serum Albumin as a Predictor of Survival after Interval Debulking Surgery for Advanced Ovarian Cancer (AOC): A Retrospective Study. <i>Journal of Investigative Surgery</i> , 2022, 35, 426-431.	0.6	7
416	High-throughput approaches for precision medicine in high-grade serous ovarian cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 134.	6.9	36
417	Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. <i>Gynecologic Oncology</i> , 2020, 159, 434-441.	0.6	16
418	Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer. <i>Pharmacogenomics</i> , 2020, 21, 995-1010.	0.6	2
419	A descriptive study of the clinico-pathological and surgical characteristics of patients with primary epithelial ovarian cancer. A cross sectional study. <i>Annals of Medicine and Surgery</i> , 2020, 59, 254-257.	0.5	0
420	The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. <i>Gynecologic Oncology</i> , 2020, 158, 653-658.	0.6	29
423	Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1935-1942.	1.2	15
424	Development of a decision aid for primary treatment of patients with advanced-stage ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 837-844.	1.2	2
425	Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1915-1921.	1.2	29
426	Treatment of epithelial ovarian cancer. <i>BMJ</i> , The, 2020, 371, m3773.	3.0	359
427	Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8300.	1.8	10
428	Laparoscopic cytoreduction After Neoadjuvant Chemotherapy (LANCE). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1450-1454.	1.2	33
429	A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 614-621.	0.6	13
430	Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction. <i>Diagnostics</i> , 2020, 10, 568.	1.3	6
432	Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer. <i>JAMA Network Open</i> , 2020, 3, e2013940.	2.8	53

#	ARTICLE	IF	CITATIONS
433	The Significance of Preoperative Computed Tomography for Predicting Optimal Cytoreduction in Advanced Ovarian Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 915-923.	0.8	2
434	Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer. <i>Medicine (United States)</i> , 2020, 99, e22100.	0.4	2
435	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1569-1575.	1.2	10
436	Improved identification of core biomarkers and drug repositioning for ovarian cancer: an integrated bioinformatics approach. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2020, 9, 1.	1.2	1
437	Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer. <i>World Journal of Surgical Oncology</i> , 2020, 18, 200.	0.8	5
438	Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9492.	1.8	28
439	Aggressive surgery could overcome the extent of initial peritoneal dissemination for advanced ovarian, fallopian tube, and peritoneal carcinoma. <i>Scientific Reports</i> , 2020, 10, 21307.	1.6	4
440	Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 699-705.	0.6	15
441	Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). <i>International Journal of Surgical Oncology</i> , 2020, 2020, 1-14.	0.3	2
442	Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer. <i>Tumor Biology</i> , 2020, 42, 101042832097140.	0.8	6
443	Radical Surgical Procedures in Advanced Ovarian Cancer and Differences Between Primary and Interval Debulking Surgery. <i>Anticancer Research</i> , 2020, 40, 5869-5875.	0.5	4
444	Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 687-691.	0.6	6
445	Primary and Interval Debulking Surgery Provide Similar Survival and Platinum Sensitivity Outcomes in Advanced Ovarian Cancer: A Retrospective Study. <i>Anticancer Research</i> , 2020, 40, 3925-3929.	0.5	4
446	Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016. <i>JAMA Network Open</i> , 2020, 3, e2017517.	2.8	31
447	Tumor shapes effect on metastatic state: A theoretical derivation embedding thermodynamic laws. <i>Chinese Journal of Physics</i> , 2020, 68, 684-698.	2.0	3
448	Neoadjuvant Chemotherapy for Patients With Diaphragmatic Lesions: A Prognostic Postoperative Analysis. <i>In Vivo</i> , 2020, 34, 1277-1281.	0.6	1
449	Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1689-1696.	0.5	12
450	Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer. <i>Anticancer Research</i> , 2020, 40, 2765-2770.	0.5	2

#	ARTICLE	IF	CITATIONS
451	Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study. <i>Oncolmmunology</i> , 2020, 9, 1760067.	2.1	29
452	Real-world treatment patterns in patients with advanced (stage III-IV) ovarian cancer in the USA and Europe. <i>Future Oncology</i> , 2020, 16, 1013-1030.	1.1	4
453	An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1479-1492.	0.9	8
454	Functional tumour burden of peritoneal carcinomatosis derived from DWI could predict incomplete tumour debulking in advanced ovarian carcinoma. <i>European Radiology</i> , 2020, 30, 5551-5559.	2.3	10
455	How Should we Perform a Preoperative Multidimensional Assessment of Elderly Patients with Advanced Ovarian Cancer?. <i>Journal of Investigative Surgery</i> , 2020, 34, 1-2.	0.6	1
456	Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial. <i>BMC Cancer</i> , 2020, 20, 385.	1.1	4
457	Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. <i>Gynecologic Oncology</i> , 2020, 158, 16-24.	0.6	40
458	Robotic surgery for gynecologic cancers: indications, techniques and controversies. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 828-843.	0.6	11
459	First-Line Management of Advanced High-Grade Serous Ovarian Cancer. <i>Current Oncology Reports</i> , 2020, 22, 64.	1.8	30
460	A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. <i>Gynecologic Oncology</i> , 2020, 158, 608-613.	0.6	23
461	Diagnostic Reliability, Accuracy and Safety of Ultrasound-guided Biopsy and Ascites Puncture in Primarily Inoperable Ovarian Tumours. <i>Anticancer Research</i> , 2020, 40, 3527-3534.	0.5	7
462	Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward or too much risk?. <i>Gynecologic Oncology</i> , 2020, 157, 561-562.	0.6	2
463	A Co-Delivery System of Curcumin and p53 for Enhancing the Sensitivity of Drug-Resistant Ovarian Cancer Cells to Cisplatin. <i>Molecules</i> , 2020, 25, 2621.	1.7	13
464	Molecular Imaging of Peritoneal Carcinomatosis in Ovarian Carcinoma. <i>American Journal of Roentgenology</i> , 2020, 215, 305-312.	1.0	10
465	Interval Debulking Surgery for Advanced Ovarian Cancer in Elderly Patients (>=70 y): Does the Age Matter?. <i>Journal of Investigative Surgery</i> , 2021, 34, 1023-1030.	0.6	9
466	Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2020, 157, 599-605.	0.6	5
467	Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. <i>Drugs in R and D</i> , 2020, 20, 55-73.	1.1	84
468	Postneoadjuvant Chemotherapy Response in Advanced Ovarian Cancer: Radiological and Clinical Implications. <i>Academic Radiology</i> , 2020, 27, 958-959.	1.3	1

#	ARTICLE	IF	CITATIONS
469	30 Years of Experience in the Management of Stage III and IV Epithelial Ovarian Cancer: Impact of Surgical Strategies on Survival. <i>Cancers</i> , 2020, 12, 768.	1.7	18
470	Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. <i>BMC Cancer</i> , 2020, 20, 185.	1.1	15
471	Ovarian cancer surgery. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 193-197.	0.3	1
472	EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1762.	1.7	17
473	Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study. <i>Gynecologic Oncology</i> , 2020, 158, 597-602.	0.6	6
474	Cul4B promotes the progression of ovarian cancer by upregulating the expression of CDK2 and CyclinD1. <i>Journal of Ovarian Research</i> , 2020, 13, 76.	1.3	22
475	Chemotherapy-associated foam cell aggregates as a prognostic factor in patients with pelvic high-grade serous carcinoma receiving neo-adjuvant chemotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 429-436.	1.4	0
476	Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites. <i>Gynecologic Oncology</i> , 2020, 157, 398-404.	0.6	5
477	Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. <i>Scientific Reports</i> , 2020, 10, 2757.	1.6	134
478	Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 379-386.	0.6	23
479	The role of changes in systemic inflammatory response markers during neoadjuvant chemotherapy in predicting suboptimal surgery in ovarian cancer. <i>Current Problems in Cancer</i> , 2020, 44, 100536.	1.0	1
480	Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 425-431.	1.0	25
481	Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis. <i>Gynecologic Oncology</i> , 2020, 157, 209-213.	0.6	26
482	Use of Transabdominal Ultrasound for the detection of intra-peritoneal tumor engraftment and growth in mouse xenografts of epithelial ovarian cancer. <i>PLoS ONE</i> , 2020, 15, e0228511.	1.1	8
483	Positron Emission Tomography/Computed Tomography in Platinum-sensitive Recurrent Ovarian Cancer: A Single-center Italian Study. <i>Anticancer Research</i> , 2020, 40, 2191-2197.	0.5	6
484	Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer. <i>Drug Discovery Today</i> , 2020, 25, 1232-1238.	3.2	28
485	Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1235.	1.0	7
486	Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis. <i>Gynecologic Oncology</i> , 2020, 158, 54-58.	0.6	10

#	ARTICLE	IF	CITATIONS
487	Outcomes of Advanced Epithelial Ovarian Cancers Treated with Neoadjuvant Chemotherapy and Interval Debulking Surgery: An Audit from a Tertiary Care Referral Center in India. <i>Indian Journal of Gynecologic Oncology</i> , 2020, 18, 1.	0.1	1
488	Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. <i>European Journal of Cancer</i> , 2020, 130, 114-125.	1.3	134
489	Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations. <i>Surgical Oncology</i> , 2020, 34, 40-45.	0.8	4
490	Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management. <i>Gynecologic Oncology</i> , 2020, 157, 572-577.	0.6	19
491	Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy. <i>Medicine (United States)</i> , 2020, 99, e19931.	0.4	6
492	Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 845-852.	1.2	29
493	Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival. <i>Journal of Translational Medicine</i> , 2020, 18, 134.	1.8	15
494	Neoadjuvant chemotherapy and the complexity of operative procedure in advanced epithelial ovarian cancer: a retrospective analysis. <i>International Journal of Surgery Oncology</i> , 2021, 3, 59.	0.2	0
495	Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 205-212.	0.6	4
496	Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?. <i>Annals of Surgical Oncology</i> , 2021, 28, 3605-3615.	0.7	5
497	Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 45-50.	0.6	12
498	BRCA1/2 status and chemotherapy response score to tailor ovarian cancer surgery. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103128.	2.0	6
499	Natural language processing with machine learning to predict outcomes after ovarian cancer surgery. <i>Gynecologic Oncology</i> , 2021, 160, 182-186.	0.6	35
500	Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications. <i>European Journal of Surgical Oncology</i> , 2021, 47, 181-187.	0.5	5
501	Diagnostic performance of ultrasound in assessing the extension of the disease in patients with suspicion of malignant ovarian tumor: correlation between ultrasound parameters and Fagotti's score. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 279-285.	1.2	2
502	Surgical Management of Gynecologic Cancers. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 69-88.	0.6	3
503	Propensity score matching confirms that primary surgery or neoadjuvant chemotherapy result in equivalent survival within a comprehensive cohort of patients with high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 24-31.	0.6	5
504	The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 153, 417-423.	1.0	9

#	ARTICLE	IF	CITATIONS
505	Objective responses to first-line neoadjuvant carboplatin+paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 277-288.	5.1	34
506	Asian perspective on debulking surgery for advanced ovarian cancer: An E-survey. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1111-1116.	0.5	3
507	Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2021, 107, 100-109.	0.6	8
508	Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 32-39.	0.6	20
509	Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 519-531.	2.0	22
510	An Italian National Survey on Ovarian Cancer Treatment at first diagnosis. There's None so Deaf as those who will not Hear. <i>Journal of Cancer</i> , 2021, 12, 4443-4454.	1.2	5
511	The role of exploratory laparoscopy in surgical planning for ultra-radical surgery for ovarian cancer: a narrative review. <i>Gynecology and Pelvic Medicine</i> , 0, .	0.1	0
512	A Prediction Model for Optimal Primary Debulking Surgery Based on Preoperative Computed Tomography Scans and Clinical Factors in Patients With Advanced Ovarian Cancer: A Multicenter Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2020, 10, 611617.	1.3	9
514	Rectosigmoid resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer: morbidity of gynecologic oncology vs. colorectal team. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e42.	1.0	6
515	Identification of Novel lncRNAs in Ovarian Cancer and Their Impact on Overall Survival. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1079.	1.8	7
516	Epithelial Ovarian Cancer and Cancer Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1330, 21-32.	0.8	4
518	Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids. , 2021, , .		0
519	The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease. <i>Journal of Cancer</i> , 2021, 12, 946-953.	1.2	2
520	Multidisciplinary Surgical Approach to Increase Complete Cytoreduction Rates for Advanced Ovarian Cancer in a Tertiary Gynecologic Oncology Center. <i>Annals of Surgical Oncology</i> , 2021, 28, 4553-4560.	0.7	11
521	The role of multiple bowel resections in advanced ovarian cancer: survival and surgical outcomes—a narrative review. <i>Gynecology and Pelvic Medicine</i> , 0, .	0.1	0
522	Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. <i>The Cochrane Library</i> , 2021, 2, CD005343.	1.5	29
523	Incidence of venous thromboembolism after standard treatment in patients with epithelial ovarian cancer in Korea. <i>Cancer Medicine</i> , 2021, 10, 2045-2053.	1.3	2
524	Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 632195.	1.3	3

#	ARTICLE	IF	CITATIONS
525	Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis. <i>Journal of Oncology</i> , 2021, 2021, 1-11.	0.6	3
526	Network pharmacology-based study to explore the mechanism of the Yiqi Gubiao pill in lung cancer treatment. <i>Oncology Letters</i> , 2021, 21, 321.	0.8	4
527	Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 191-226.	2.3	356
528	Minimally invasive surgery (robotic or laparoscopic) versus laparotomy for advanced ovarian cancer. <i>The Cochrane Library</i> , 0, , .	1.5	0
529	Analysis of Morbidity, Mortality and Survival Pattern Following Surgery for Borderline Ovarian and Malignant Ovarian Tumour in Tertiary Care Centre. <i>Journal of Obstetrics and Gynecology of India</i> , 2021, 71, 297-303.	0.3	1
530	Prognostic and clinical significance of Solute Carrier Family 7 Member 1 in ovarian cancer. <i>Translational Cancer Research</i> , 2021, 10, 602-612.	0.4	6
531	Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. <i>Cancers</i> , 2021, 13, 626.	1.7	26
532	Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103209.	2.0	11
533	Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer. <i>Radiology and Oncology</i> , 2021, 55, 341-346.	0.6	11
534	Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 646135.	1.3	5
535	Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study. <i>Journal of Ovarian Research</i> , 2021, 14, 49.	1.3	22
536	Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy. <i>Gynecologic Oncology</i> , 2021, 160, 681-687.	0.6	13
537	Prediction of optimal debulking surgery in ovarian cancer. <i>Gland Surgery</i> , 2021, 10, 1173-1181.	0.5	12
538	pH-Responsive Nanomedicine for Image-Guided Drug Delivery. , 2021, , 39-68.		1
539	Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 116.	3.5	23
540	C�ncer de ovario. <i>Medicine</i> , 2021, 13, 1518-1526.	0.0	0
541	Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1021-1032.	0.8	5
542	Evaluation of Beta-Catenin Subcellular Localization and Water Channel Protein AQP1 Expression as Predictive Markers of Chemo-Resistance in Ovarian High-Grade Serous Carcinoma: Comparative Study between Preoperative Peritoneal Biopsies and Surgical Samples. <i>Diagnostics</i> , 2021, 11, 452.	1.3	4

#	ARTICLE	IF	CITATIONS
543	Ovarian Carcinoma with Peritoneal Metastasis: Rethinking of Management. Archives of Clinical and Experimental Medicine, 2021, 6, 32-36.	0.1	0
544	Cytoreductive or debulking surgery in ovarian cancer: The name does matter!. Journal of Surgical Oncology, 2021, 123, 1846-1847.	0.8	1
545	Chemotherapy Response Score Predicts Surgical Outcome and Prognosis in Tubo-Ovarian/Primary Peritoneal Cancers: A Retrospective Analysis in a Tertiary Care Centre in UK. Indian Journal of Gynecologic Oncology, 2021, 19, 1.	0.1	0
546	Survival Outcome After Interval Cytoreductive Surgery in Advanced-Stage Epithelial Ovarian Carcinoma: A Tertiary Care Centre Experience. Indian Journal of Gynecologic Oncology, 2021, 19, 1.	0.1	0
548	Narrative review of liver mobilization, diaphragm peritonectomy, full-thickness diaphragm resection, and reconstruction. Gland Surgery, 2021, 10, 1212-1217.	0.5	5
549	Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study. BMC Cancer, 2021, 21, 322.	1.1	34
550	Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study. Gynecologic Oncology, 2021, 161, 244-250.	0.6	6
551	Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review. Cancers, 2021, 13, 2067.	1.7	7
552	Noninvasive prediction of residual disease for advanced high-grade serous ovarian carcinoma by MRI-based radiomic-clinical nomogram. European Radiology, 2021, 31, 7855-7864.	2.3	22
553	Aggressive anaplastic ovarian carcinoma in a young nulliparous patient. BMJ Case Reports, 2021, 14, e241461.	0.2	0
554	Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecologic Oncology, 2021, 161, 56-62.	0.6	7
555	Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer. Scientific Reports, 2021, 11, 8111.	1.6	19
556	The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance. Seminars in Cancer Biology, 2021, 77, 182-193.	4.3	38
557	Prognostic Value and Therapeutic Implications of Pleural Carcinosis and Malignant Pleural Effusion in Advanced Epithelial Ovarian Cancer. Anticancer Research, 2021, 41, 2033-2038.	0.5	2
558	Role of systematic pelvic and para-aortic lymphadenectomy in delayed debulking surgery after six neoadjuvant chemotherapy cycles for high-grade serous ovarian carcinoma. Journal of Obstetrics and Gynaecology Research, 2021, 47, 2737-2744.	0.6	2
559	Management of advanced ovarian cancer in Spain: an expert Delphi consensus. Journal of Ovarian Research, 2021, 14, 72.	1.3	2
560	The use of neoadjuvant chemotherapy in advanced endometrial cancer. Gynecologic Oncology Reports, 2021, 36, 100725.	0.3	7
561	Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients. Frontiers in Oncology, 2021, 11, 655709.	1.3	4

#	ARTICLE	IF	CITATIONS
562	Peritoneal cancer index predicts severe complications after ovarian cancer surgery. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2915-2924.	0.5	6
563	Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 1237-1243.	0.3	6
564	Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 687-692.	0.6	14
565	M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients. <i>Gynecologic Oncology</i> , 2021, 161, 681-686.	0.6	5
566	Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II-IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103324.	2.0	6
567	Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer. <i>ESMO Open</i> , 2021, 6, 100149.	2.0	19
568	MicroRNA characteristics in epithelial ovarian cancer. <i>PLoS ONE</i> , 2021, 16, e0252401.	1.1	4
569	A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer. <i>Surgical Oncology</i> , 2021, 37, 101523.	0.8	6
570	Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 660-667.	0.6	6
571	Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	10
572	Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGL international collaborative registry. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1420-1426.	0.5	20
573	CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer. <i>Cancer Science</i> , 2021, 112, 3655-3668.	1.7	9
575	Multimodal Treatment of Primary Advanced Ovarian Cancer. <i>Anticancer Research</i> , 2021, 41, 3253-3260.	0.5	14
576	Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II ACOG/TGOG trial. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 262, 13-20.	0.5	3
577	Debulking surgery for malignant tumors: the current status, evidence and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1349-1362.	0.6	6
578	Prognostic Benefit of 6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers. <i>Anticancer Research</i> , 2021, 41, 4157-4161.	0.5	1
579	Treatment of advanced-stage ovarian cancer including combination of intra-abdominal chemotherapy. , 2021, 20, 28-35.	0.0	0
580	Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. <i>The Cochrane Library</i> , 2021, 2021, CD005343.	1.5	25

#	ARTICLE	IF	CITATIONS
581	GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. <i>Clinical Cancer Research</i> , 2021, 27, 5536-5545.	3.2	15
582	Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 162, 65-71.	0.6	3
583	Peroperative scoring systems for predicting the outcome of cytoreductive surgery in advanced-stage ovarian cancer – A systematic review. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1856-1861.	0.5	6
584	Primary treatment of advanced ovarian cancer: how does the “real world” practice?. <i>Future Oncology</i> , 2021, 17, 4687-4696.	1.1	2
585	Prognostic significance of Ki67 during neoadjuvant chemotherapy in primary unresectable ovarian cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 3979-3989.	0.6	1
586	Long-Term Follow-Up of Gemogenovatumel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. <i>Vaccines</i> , 2021, 9, 894.	2.1	9
587	Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response. <i>Cancers</i> , 2021, 13, 4318.	1.7	47
588	Predicting Complete Cytoreduction in Ovarian Cancer Patients by RECIST 1.1 Criteria Following Neoadjuvant Chemotherapy. <i>Indian Journal of Gynecologic Oncology</i> , 2021, 19, 1.	0.1	1
589	Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1341-1347.	1.2	4
590	The Role of Ultra-Radical Surgery in the Management of Advanced Ovarian Cancer: State of the Art. , 0, , .		0
591	Total parietal peritonectomy in primary debulking surgery for advanced ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100805.	0.3	2
592	Evaluation of Peritoneal Cancer Index as a Prognostic Marker in Primary Advanced Epithelial Ovarian Carcinoma Undergoing “Interval Cytoreductive Surgery” After Neoadjuvant Chemotherapy. <i>Journal of Gynecologic Surgery</i> , 2021, 37, 331-336.	0.0	0
593	A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA. <i>Acta Clinica Belgica</i> , 2021, , 1-13.	0.5	4
594	Cost-Effectiveness of Venous Thromboembolism Prophylaxis During Neoadjuvant Chemotherapy for Ovarian Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1075-e1084.	1.4	10
595	CA125 normalization within 60 days as an independent prognostic factor for patients with advanced epithelial ovarian cancer. <i>Cancer Biomarkers</i> , 2021, , 1-9.	0.8	2
596	Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 162, 339-344.	0.6	6
597	Total parietal peritonectomy performed during interval cytoreductive surgery for advanced epithelial serous ovarian cancer results in a low incidence of platinum resistant recurrence— results of a prospective multi-centre study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2150-2157.	0.5	5
598	Surgical Techniques and Outcomes of Colorectal Anastomosis after Left Hemicolectomy with Low Anterior Rectal Resection for Advanced Ovarian Cancer. <i>Cancers</i> , 2021, 13, 4248.	1.7	0

#	ARTICLE	IF	CITATIONS
599	Addressing hepatic metastases in ovarian cancer: Recent advances in treatment algorithms and the need for a multidisciplinary approach. <i>World Journal of Hepatology</i> , 2021, 13, 1122-1131.	0.8	2
600	Role of adjuvant and post-surgical treatment in gynaecological cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 78, 2-13.	1.4	9
601	A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction. <i>Cancers</i> , 2021, 13, 4925.	1.7	2
602	Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. <i>JAMA Oncology</i> , 2021, 7, 1782.	3.4	21
603	The role of CT, PET-CT, and MRI in ovarian cancer. <i>British Journal of Radiology</i> , 2021, 94, 20210117.	1.0	15
604	Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. <i>The Cochrane Library</i> , 0, , .	1.5	4
605	Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer. <i>Gynecologic Oncology</i> , 2021, 162, 645-651.	0.6	8
606	Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients. <i>Future Oncology</i> , 2021, 17, 3607-3614.	1.1	3
607	Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer. <i>Gynecologic Oncology</i> , 2021, 162, 599-605.	0.6	5
608	Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2021, 41, 4603-4607.	0.5	0
609	Role of the Cardiophrenic Lymph Node Status After Neoadjuvant Chemotherapy in Primary Advanced Ovarian Cancer. <i>Anticancer Research</i> , 2021, 41, 5025-5031.	0.5	2
610	Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100870.	0.3	2
611	Malignant diseases of the ovary, fallopian tube, and peritoneum. , 2022, , 707-753.e7.		2
613	Experience with PlasmaJetâ„¢ in debulking surgery in 87 patients with advancedâ€stage ovarian cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1109-1114.	0.8	6
614	Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma. <i>Journal of Cancer</i> , 2021, 12, 2295-2316.	1.2	26
615	CT-Based Fagotti Scoring System for Non-Invasive Prediction of Cytoreduction Surgery Outcome in Patients with Advanced Ovarian Cancer. <i>Korean Journal of Radiology</i> , 2021, 22, 1481.	1.5	9
616	Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer. <i>JAMA Network Open</i> , 2020, 3, e2028612.	2.8	19
617	Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. <i>Obstetrics and Gynecology</i> , 2021, 137, 108-121.	1.2	150

#	ARTICLE	IF	CITATIONS
620	African American women with advanced-stage ovarian cancer have worse outcomes regardless of treatment type. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1018-1025.	1.2	3
621	Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 491-497.	1.2	20
622	Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1554-1561.	1.2	7
623	Dexmedetomidine Regulates Proliferation, Apoptosis, Migration, and Invasion in Ovarian Cancer Cells via MiR-155-HIF-1 α Axis. <i>Medical Science Monitor</i> , 2019, 25, 10164-10172.	0.5	11
624	Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer. <i>PLoS ONE</i> , 2017, 12, e0183754.	1.1	10
625	Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer. <i>Current Gynecologic Oncology</i> , 2017, 15, 5-23.	0.1	16
626	RETROSPECTIVE ANALYSIS OF LONG-TERM SURVIVAL OUTCOMES OF PRIMARY CYTOREDUCTION AND NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH OVARIAN CANCER STAGE III&IV. <i>Malignant Tumours</i> , 2018, 8, 86-94.	0.1	2
627	BRCA mutations in the manifestation and treatment of ovarian cancer. <i>Oncotarget</i> , 2017, 8, 97657-97670.	0.8	32
628	Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?. <i>Annals of Translational Medicine</i> , 2020, 8, 1710-1710.	0.7	35
629	Neoadjuvant chemotherapy in advanced ovarian cancer: optimal patient selection and response evaluation. <i>Chinese Clinical Oncology</i> , 2018, 7, 58-58.	0.4	12
630	Impact of Neoadjuvant Chemotherapy on the Rate of Bowel Resection in Advanced Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2016, 36, 4865-4872.	0.5	14
631	Bevacizumab for Ovarian Cancer at High Risk of Progression: Reproducibility of Trial Results in "Real-world" Patients. <i>Anticancer Research</i> , 2016, 36, 4947-4950.	0.5	5
632	Surgical Outcomes and Morbidity After Radical Surgery for Ovarian Cancer in Aberdeen Royal Infirmary, the Northeast of Scotland Gynaecologic Oncology Centre. <i>Anticancer Research</i> , 2018, 38, 923-928.	0.5	10
633	Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis. <i>Minerva Medica</i> , 2019, 110, 330-340.	0.3	25
634	A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer. <i>Yonsei Medical Journal</i> , 2020, 61, 284.	0.9	6
635	A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e112.	1.0	15
636	Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e113.	1.0	3
637	Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e81.	1.0	22

#	ARTICLE	IF	CITATIONS
638	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e17.	1.0	22
639	Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e23.	1.0	3
640	How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e26.	1.0	5
641	Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e34.	1.0	17
642	Incidence trends for epithelial peritoneal, ovarian, and fallopian tube cancer during 1999–2016: a retrospective study based on the Korean National Cancer Incidence Database. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e56.	1.0	5
643	Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SCOG SUNNY (SOC-2) trial concept. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e86.	1.0	22
644	Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer. <i>Oncology Letters</i> , 2020, 19, 2713-2720.	0.8	10
645	Expression and clinical significance of methyl-CpG binding domain protein 2 in high-grade serous ovarian cancer. <i>Oncology Letters</i> , 2020, 20, 2749-2756.	0.8	7
646	Laparoscopy and computed tomography imaging in advanced ovarian tumors: A roadmap for prediction of optimal cytoreductive surgery. <i>Gynecology and Minimally Invasive Therapy</i> , 2018, 7, 66.	0.2	13
647	Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. <i>Indian Journal of Cancer</i> , 2018, 55, 50.	0.2	14
648	Early Assessment of Response to Neoadjuvant Chemotherapy with ^{18}F -FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1211-1218.	1.3	4
649	Clinical Prognostic Factors in pre-and Post-Menopausal Women with Ovarian Carcinoma. <i>Acta Endocrinologica</i> , 2018, 14, 353-359.	0.1	8
650	Presence and role of stem cells in ovarian cancer. <i>World Journal of Stem Cells</i> , 2019, 11, 383-397.	1.3	69
651	Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 150-157.	0.6	8
652	Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients. <i>World Journal of Methodology</i> , 2015, 5, 196.	1.1	10
653	NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 896-909.	2.3	200
654	Ovarian Cancer: Primary Advanced and Recurrent Disease. <i>UNIPA Springer Series</i> , 2021, , 861-883.	0.1	0
655	Feature Selection is Critical for 2-Year Prognosis in Advanced Stage High Grade Serous Ovarian Cancer by Using Machine Learning. <i>Cancer Control</i> , 2021, 28, 107327482110446.	0.7	18

#	ARTICLE	IF	CITATIONS
656	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e95.	1.0	5
657	Clinical Availability of Tumour Biopsy Using Diagnostic Laparoscopy for Advanced Ovarian Cancer. <i>In Vivo</i> , 2021, 35, 3325-3331.	0.6	6
658	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 61-85.	1.0	145
659	Is there a correlation of positive peritoneal washing cytology during interval debulking surgery on the survival outcomes of ovarian cancer patients? A systematic review and meta-analysis of the literature. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2022, 51, 102256.	0.6	4
660	Cancer Patient Tissueoid with Self-Homing Nano-Targeting of Metabolic Inhibitor. <i>Advanced Science</i> , 2021, 8, 2102640.	5.6	3
661	Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study. <i>Gynecologic Oncology</i> , 2022, 164, 120-128.	0.6	8
662	Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy. <i>Journal of Minimally Invasive Gynecology</i> , 2022, 29, 375-384.	0.3	0
663	Total Colectomy as a Part of Ultra-Radical Surgery for Ovarian Cancer—Short- and Long-Term Outcomes. <i>Current Oncology</i> , 2021, 28, 4223-4233.	0.9	0
664	Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 4829.	1.0	3
665	Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients. <i>International Journal of Clinical Oncology</i> , 2022, 27, 441-447.	1.0	2
666	Diagnosis and Management of Epithelial Ovarian Cancer. , 2016, , 1-18.		0
667	<i>Gynecologic Oncology</i> . , 2016, , 491-521.		0
668	Debulking Surgery: Interval Debulking Surgery Versus Primary: Pros and Cons on How to Evaluate Quality. , 2017, , 33-42.		0
669	Ovarian Cancer in Sub-Saharan Africa: Current State and Future. , 2017, , 141-151.		1
670	Ovarialkarzinom bei der alten und geriatrischen Patientin. , 2017, , 1-11.		0
671	Diagnosis and Management of Epithelial Ovarian Cancer. , 2017, , 909-926.		0
672	Primary Chemotherapy and Targeted Molecular Therapy of Epithelial Ovarian Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , 207-224.	0.0	0
673	Strategies for the Management of Epithelial Ovarian Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , 155-164.	0.0	0

#	ARTICLE	IF	CITATIONS
674	Ovarian cancer: current approaches to classification, diagnostics, staging and differential management of patients. <i>Journal of Obstetrics and Women's Diseases</i> , 2017, 66, 55-66.	0.0	1
675	Association between Preoperational Blood Profiles and Post Operational Complications in Patients Suffering Epithelial Ovarian Cancer. <i>MOJ Women S Health</i> , 2017, 6, .	0.2	0
676	Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer. <i>Anticancer Research</i> , 2017, 37, 6879-6886.	0.5	5
677	Ovarialkarzinom bei der alten und geriatrischen Patientin. , 2018, , 417-427.		0
679	Neoadjuvant chemotherapy for advanced ovarian cancer. <i>Onkologie (Czech Republic)</i> , 2018, 12, 78-81.	0.0	0
680	What first-line therapy is optimal for patients with advanced ovarian cancer?. <i>Current Gynecologic Oncology</i> , 2018, 16, 89-95.	0.1	0
681	Bevacizumab in epithelial ovarian cancer treatment, efficiency and risks. <i>Onkologie (Czech Republic)</i> , 2018, 12, 198-202.	0.0	0
682	Surgical Management of the Adnexal Mass. <i>Current Women's Health Reviews</i> , 2018, 15, 23-26.	0.1	0
684	Patterns of care for ovarian cancer. <i>Cancer Research Statistics and Treatment</i> , 2019, 2, 217.	0.1	3
685	Primary Debulking Surgery (Advanced). <i>Comprehensive Gynecology and Obstetrics</i> , 2019, , 341-351.	0.0	0
687	Non-inferiority Randomized Controlled Trials. , 2019, , 125-134.		0
688	Gynecologic Disorders in the Older Woman. , 2019, , 1-38.		0
689	The usefulness of diagnostic laparoscopy for advanced ovarian cancer patients.. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2019, 35, 92-97.	0.0	0
690	Outline of Surgical Treatments. <i>Comprehensive Gynecology and Obstetrics</i> , 2019, , 313-324.	0.0	0
691	In patients with advanced ovarian cancer, primary suboptimal surgery has better survival outcome than interval suboptimal surgery. <i>Journal of the Turkish German Gynecology Association</i> , 2019, 20, 31-36.	0.2	1
695	Long-term outcomes of surgical treatment of common ovarian cancer at the stage of primary debulking. <i>OnkologiĀeskaĀĀ KoloproktologiĀĀ</i> , 2019, 9, 46-53.	0.1	0
696	Primary ovarian cancer: possibilities for improving treatment outcomes. <i>Meditinskiy Sovet</i> , 2019, , 150-156.	0.1	1
699	Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers. <i>Journal of Ovarian Research</i> , 2020, 13, 61.	1.3	3

#	ARTICLE	IF	CITATIONS
700	Characteristics of oncological care in the reality of COVID-19 pandemic: views of a lawyer and a clinician. <i>Opuholi Zenskoj Reproktivnoj Sistemy</i> , 2020, 16, 85-90.	0.1	2
701	Is it possible to improve primary therapy of advanced ovarian cancer?. <i>Meditinskiy Sovet</i> , 2020, , 128-135.	0.1	0
702	A Single Centre Randomised Control Study to Assess the Impact of Pre-Operative Carbohydrate Loading on Women Undergoing Major Surgery for Epithelial Ovarian Cancer. <i>Cureus</i> , 2020, 12, e10169.	0.2	0
703	Neoadjuvant chemotherapy for IIIC stage ovarian cancer - case report. <i>Journal of Education, Health and Sport</i> , 2020, 10, 84.	0.0	0
704	The role of factor XIII in surgery for advanced stage of epithelial ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2021, , 1.	0.8	0
707	ĐŠĐ°Đ° Ñ•Đ¾Ñ,Đ±Đ,Ñ€Đ°ÑŽ Đ±Đ¾Đ»ÑCED½Ñ«Ñ... ĐĐ»Ñ•Đ;ĐµÑ€Đ²Đ,Ñ‡Đ½Đ¾Đ¹ Đ, Đ,Đ½Ñ,ĐµÑ€Đ²Đ°Đ»ÑCED½Đ¾ĐĐ Ñ†Đ,Ñ,Đ¾		
708	SCORPION study: is it time to call primary debulking surgery superior?. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 310-310.	1.2	1
709	Learning curve for gynecological oncologists in performing upper abdominal surgery. <i>Minerva Ginecologica</i> , 2020, 72, 325-331.	0.8	2
710	First-line treatment of advanced ovarian cancer: an expert update. <i>Libri Oncologici</i> , 2020, 48, 77-84.	0.1	0
711	Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence. <i>Annals of Translational Medicine</i> , 2020, 8, 1707-1707.	0.7	8
712	Gynecologic Disorders in the Older Woman. , 2020, , 683-719.		0
713	Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. <i>Yonsei Medical Journal</i> , 2020, 61, 935.	0.9	0
715	Management options for gynecological cancers in low- to middle-income countries amidst COVID-19 pandemic. <i>Journal of Cancer Research and Practice</i> , 2020, 7, 121.	0.2	1
716	Surgical and Survival Outcomes with Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Longitudinal Study in a Tertiary Cancer Center. <i>Journal of SAFOG</i> , 2020, 12, 27-30.	0.1	0
717	Neoadjuvant chemotherapy for advanced stage endometrial cancer: A systematic review. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100887.	0.3	9
718	National trends in bowel and upper abdominal procedures in ovarian cancer surgery. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1195-1202.	1.2	6
719	Crossâ€validation of genes potentially associated with neoadjuvant chemotherapy and platinumâ€based chemoresistance in epithelial ovarian carcinoma. <i>Oncology Reports</i> , 2020, 44, 909-926.	1.2	3
720	Clinicopathological and Immunohistochemical Study of High Grade Serous Ovarian Carcinoma. <i>Medicine Updates</i> , 2020, 2, 15-37.	0.0	0

#	ARTICLE	IF	CITATIONS
721	Lymph nodes dissection in advanced ovarian cancer. <i>Reproductive Endocrinology</i> , 2020, .	0.0	0
722	Ovarian Cancer: Current Treatment and Patient Management. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 271-273.	0.2	5
723	Alternative Payment Models in Medical Oncology: Assessing Quality-of-Care Outcomes Under Partial Capitation. <i>American Health and Drug Benefits</i> , 2018, 11, 371-378.	0.5	6
724	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. <i>JCSM Clinical Reports</i> , 2021, 6, 11-16.	0.5	0
725	Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study). <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2021-002888.	1.2	4
726	Options for the Treatment of Mucinous Ovarian Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 114.	1.3	9
727	Aggregation-induced emission luminogens for image-guided surgery in non-human primates. <i>Nature Communications</i> , 2021, 12, 6485.	5.8	35
728	Treatment outcomes and predictive factors in patients ≥70 years old with advanced ovarian cancer. <i>Journal of Surgical Oncology</i> , 2021, , .	0.8	3
729	Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer. <i>Cancers</i> , 2021, 13, 5899.	1.7	9
730	Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. <i>Current Oncology</i> , 2022, 29, 231-242.	0.9	3
732	Risks factors for anastomotic leakage in advanced ovarian cancer: A systematic review and meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 269, 3-15.	0.5	6
733	Prospective study of the role of HE4 and CA125 in treatment and follow-up in ovarian cancer patients. <i>Obstetrics & Gynecology International Journal</i> , 2020, 11, 185-190.	0.0	0
735	Survival After Primary Surgery Compared With Neoadjuvant Chemotherapy in Early-stage Ovarian Cancer. <i>Anticancer Research</i> , 2020, 40, 6003-6008.	0.5	0
736	Neoadjuvant Chemotherapy Followed by Surgery versus Primary Surgery in Advanced Epithelial Ovarian Cancer: A Review of Outcomes at National Institute of Cancer Research Hospital in Bangladesh. <i>Journal of Cancer Therapy</i> , 2021, 12, 621-633.	0.1	1
737	Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-002908.	1.2	1
738	Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 810099.	1.3	2
739	Hyperthermic Intraperitoneal Chemotherapy in the Treatment Armamentarium of Epithelial Ovarian Cancer: Time to End the Dichotomy. <i>Visceral Medicine</i> , 2022, 38, 109-119.	0.5	2
740	Enhanced Anti-Proliferative Effect of Carboplatin in Ovarian Cancer Cells Exploiting Chitosan-Poly (Lactic Glycolic Acid) Nanoparticles. <i>Recent Patents on Nanotechnology</i> , 2023, 17, 74-82.	0.7	3

#	ARTICLE	IF	CITATIONS
741	Prognostic value of complete metabolic response on 18F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	3
743	Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers. <i>Gynecologic Oncology</i> , 2022, 164, 295-303.	0.6	2
744	Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer. <i>Gynecologic Oncology</i> , 2022, 164, 341-347.	0.6	1
745	Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	6
746	Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review. <i>Future Oncology</i> , 2022, 18, 1627-1650.	1.1	3
747	Low-Grade Serous Carcinoma of the Ovary: The Current Status. <i>Diagnostics</i> , 2022, 12, 458.	1.3	12
748	Primary and metastatic peritoneal surface malignancies. <i>Nature Reviews Disease Primers</i> , 2021, 7, 91.	18.1	87
749	MiR-506-3p suppresses the proliferation of ovarian cancer cells by negatively regulating the expression of MTMR6. <i>Journal of Biosciences</i> , 2019, 44, .	0.5	8
750	Posterior pelvic exenteration, a crucial component in the surgeon's toolbox for optimizing surgical cytoreduction for advanced ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	2
752	Overall Survival and Related Factors of Advanced-stage Epithelial Ovarian Cancer Patients Underwent Debulking Surgery in Jakarta, Indonesia: A Single-center Experience. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 265-280.	0.1	3
753	Letter to the Editor: Comment on "Cyoreductive Surgery with or without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial". <i>Annals of Surgical Oncology</i> , 2022, 29, 3351-3352.	0.7	2
755	Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2022, 101, 334-343.	1.3	5
756	Differences in Patterns of Recurrence Between Primary and Interval Debulking Surgery for Advanced Ovarian Cancer. <i>Anticancer Research</i> , 2022, 42, 2003-2008.	0.5	2
757	Feasibility of a Multimodal Prehabilitation Programme in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer: A Pilot Study. <i>Cancers</i> , 2022, 14, 1635.	1.7	13
758	Perspectives on Ovarian Cancer 1809 to 2022 and Beyond. <i>Diagnostics</i> , 2022, 12, 791.	1.3	7
759	The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 263.	1.1	3
760	The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 1665-1672.	0.8	6
761	The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery. <i>Cancer Medicine</i> , 2022, , .	1.3	5

#	ARTICLE	IF	CITATIONS
762	Clinical view of gynecologic intraoperative frozen section diagnosis. <i>Gynecology and Obstetrics Clinical Medicine</i> , 2022, 2, 6-8.	0.2	2
763	Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2022, 12, 633.	1.3	4
764	Complete Laparoscopic Interval Debulking Surgery for Advanced Ovarian Cancer Achieves Similar Survival Outcomes to Open Approach: A Propensity-Matched Study. <i>Journal of Investigative Surgery</i> , 2022, 35, 1394-1401.	0.6	5
765	Computed tomographic enterography (CTE) in evaluating bowel involvement in patients with ovarian cancer. <i>Abdominal Radiology</i> , 2022, , 1.	1.0	0
766	A case report of appendiceal adenocarcinoma without gastrointestinal evidence mimicking primary ovarian cancer. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210885.	0.4	1
767	Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100951.	0.3	2
768	Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 82-89.	0.6	2
769	The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review. <i>Cancers</i> , 2022, 14, 98.	1.7	16
770	Efficacy of neoadjuvant hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer (the NHIPEC trial): study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e046415.	0.8	0
771	Scoring Systems of Peritoneal Dissemination for the Prediction of Operative Completeness in Advanced Ovarian Cancer. <i>Anticancer Research</i> , 2022, 42, 115-124.	0.5	4
772	Trends in extent of surgical cytoreduction for patients with ovarian cancer. <i>PLoS ONE</i> , 2021, 16, e0260255.	1.1	5
773	Clinical Staging of Ovarian Cancer. <i>Methods in Molecular Biology</i> , 2022, 2424, 3-10.	0.4	14
774	Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1. <i>Frontiers in Oncology</i> , 2021, 11, 795547.	1.3	39
775	Treatment of Epithelial Ovarian Cancers, Fallopian Tube Cancers and Peritoneal Surface Cancers. , 2021, , 357-365.		0
776	Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade. <i>Bulletin Du Cancer</i> , 2021, 108, S5-S12.	0.6	3
777	The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction. <i>Journal of Clinical Medicine</i> , 2021, 10, 5927.	1.0	9
778	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. <i>JCSM Clinical Reports</i> , 2021, 6, 11-16.	0.5	3
779	OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	0.6	0

#	ARTICLE	IF	CITATIONS
780	Women With Ovarian Cancer and With Fertility Preservation: A Survival Analysis Using the Surveillance, Epidemiology, and End Results Database and Construction of Nomograms to Predict Cancer-Specific Survival. <i>Frontiers in Oncology</i> , 2022, 12, 860046.	1.3	2
781	Complications after advanced ovarian cancer surgery—A population-based cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2022, , .	1.3	3
782	Clinical implementation of routine diagnostic laparoscopy to guide initial treatment in patients with advanced-stage epithelial ovarian cancer in Dutch clinical practice: Evaluation of support and a budget impact analysis. <i>Gynecologic Oncology</i> , 2022, , .	0.6	0
783	The use of biomarkers to stratify surgical care in women with ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, , .	1.1	0
784	Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction. <i>Diagnostics</i> , 2022, 12, 988.	1.3	10
785	Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer. <i>Gynecologic Oncology</i> , 2022, 165, 428-436.	0.6	5
786	Explainable Artificial Intelligence for Prediction of Complete Surgical Cytoreduction in Advanced-Stage Epithelial Ovarian Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 607.	1.1	19
787	Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases. <i>Molecules</i> , 2022, 27, 2466.	1.7	29
788	Single-Institution Retrospective Analysis of Ovarian Cancer Outcomes from the Middle Eastern Republic of Georgia. <i>Indian Journal of Gynecologic Oncology</i> , 2022, 20, 1.	0.1	0
792	Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2308.	1.7	12
793	Ovarian Cancer: Treatment and Resistance to Pharmacotherapy. <i>Reproductive Medicine</i> , 2022, 3, 127-140.	0.3	7
794	Interval debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer - retrospective study comparing surgery after 3 cycles or more of chemotherapy. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2022, 51, 102409.	0.6	2
795	Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands. <i>Annals of Surgical Oncology</i> , 2022, 29, 4833-4843.	0.7	11
796	State of the science: Contemporary front-line treatment of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 166, 18-24.	0.6	6
797	Relationship Between Neoadjuvant Chemotherapy and Log Odds of Positive Lymph Nodes and Their Prognostic Role in Advanced Ovarian Cancer Patients With Optimal Cytoreductive Surgery. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	4
798	CT of Ovarian Cancer for Primary Treatment Planning: What the Surgeon Needs to Know—Radiology In Training. <i>Radiology</i> , 2022, 304, 516-526.	3.6	4
799	Current treatment status of older patients with gynecological cancers. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 825-832.	0.6	3
800	Maximal surgical effort increases the risk of postoperative complications in the treatment of advanced ovarian cancer. <i>European Journal of Surgical Oncology</i> , 2022, 48, 2525-2530.	0.5	4

#	ARTICLE	IF	CITATIONS
801	What are the implications of radiologically abnormal cardiophrenic lymph nodes in advanced ovarian cancer? An analysis of tumour burden, surgical complexity, same-site recurrence and overall survival. <i>European Journal of Surgical Oncology</i> , 2022, 48, 2531-2538.	0.5	3
802	Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
803	Diagnostic performance of ultrasound in assessing the extension of disease in advanced ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 601.e1-601.e20.	0.7	2
804	Symptomatic or asymptomatic recurrence of ovarian cancer: does it influence survival?. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2022-003361.	1.2	0
805	Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer â€” International considerations amongst upper middle- and high-income countries (UMIC and HIC). <i>Gynecologic Oncology Reports</i> , 2022, 42, 101028.	0.3	5
806	Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles. <i>Gynecologic Oncology</i> , 2022, 166, 5-7.	0.6	0
808	Systematic lymph node dissection during interval debulking surgery for advanced epithelial ovarian cancer: a systematic review and meta-analysis. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	3
809	Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
810	Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer. <i>BMC Women's Health</i> , 2022, 22, .	0.8	2
811	Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 735.e1-735.e25.	0.7	79
812	The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer. <i>Cancers</i> , 2022, 14, 3318.	1.7	1
813	Factors Predicting Surgical Effort Using Explainable Artificial Intelligence in Advanced Stage Epithelial Ovarian Cancer. <i>Cancers</i> , 2022, 14, 3447.	1.7	15
814	Prolonged Exposition with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) May Provide Survival Benefit after Cytoreductive Surgery (CRS) in Advanced Primary Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. <i>Cancers</i> , 2022, 14, 3301.	1.7	4
815	Retrospective Analysis of Total Parietal Peritonectomy Without Systematic Lymphadenectomy for Advanced Epithelial Ovarian Cancer. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 482-488.	0.3	0
816	Red Cell Distribution Width and High Grade Serous Ovarian Cancer: Prognostic Marker?. <i>Indian Journal of Gynecologic Oncology</i> , 2022, 20, .	0.1	0
817	Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in highâ€grade serous ovarian cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 0, , .	1.3	2
818	Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 166, 453-459.	0.6	4
819	Highly Aggressive Surgery Benefits in Patients With Advanced Ovarian Cancer. <i>Anticancer Research</i> , 2022, 42, 3707-3716.	0.5	3

#	ARTICLE	IF	CITATIONS
820	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 919-930.	5.1	11
821	Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer. <i>Annals of the Academy of Medicine, Singapore</i> , 2015, 44, 421-433.	0.2	2
822	Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
823	Maintenance therapy for newly diagnosed epithelial ovarian cancer—a review. <i>Journal of Ovarian Research</i> , 2022, 15, .	1.3	11
824	Magnetic Resonance Imaging and Diffusion Weighted Imaging-Based Histogram in Predicting Mesenchymal Transition High-Grade Serous Ovarian Cancer. <i>Academic Radiology</i> , 2023, 30, 1118-1128.	1.3	2
825	The impact of neoadjuvant chemotherapy on the tumor microenvironment in advanced high-grade serous carcinoma. <i>Oncogenesis</i> , 2022, 11, .	2.1	2
826	Primary Cervical Carcinosarcoma: Report of a Rare Case. <i>The Surgery Journal</i> , 2022, 08, e174-e178.	0.3	1
827	Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2022, 14, 3554.	1.7	3
828	Does MIS Play a Role in the Treatment of Advanced Ovarian Cancer?. <i>Cancers</i> , 2022, 14, 3579.	1.7	3
829	Primary or Interval Debulking Surgery in Advanced Ovarian Cancer: a Personalized Decision—a Literature Review. <i>Current Oncology Reports</i> , 0, , .	1.8	0
830	Chemoresistance in Ovarian Cancer: The Role of Malignant Ascites. , 0, , 27-42.		1
831	Preoperative ¹⁸ F-NaF PET/CT score can predict incomplete resection after debulking surgery for advanced serous ovarian cancer better than CT score, MTV, tumor markers and hematological markers. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 0, , .	1.3	4
832	Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. <i>Gynecologic Oncology</i> , 2022, 167, 11-21.	0.6	5
833	No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
834	UTERUS 11 is a negative trial. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2022-003953.	1.2	0
835	Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis. <i>ESMO Open</i> , 2022, 7, 100558.	2.0	7
836	Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. <i>ESMO Open</i> , 2022, 7, 100586.	2.0	20
837	Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer. <i>PharmacoEconomics - Open</i> , 2022, 6, 811-822.	0.9	4

#	ARTICLE	IF	CITATIONS
838	Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. The Cochrane Library, 2022, 2022, .	1.5	3
839	Análise de toxicidades relacionadas ao protocolo carboplatina e paclitaxel em pacientes com câncer de ovário. Revista Brasileira De Farmácia Hospitalar E Serviços De Saúde, 2022, 13, 823.	0.0	0
840	Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer. Frontiers in Oncology, 0, 12, .	1.3	1
841	PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer. , 0, , .		0
842	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20 years' experience. BMC Surgery, 2022, 22, .	0.6	1
843	Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study. Cancers, 2022, 14, 4362.	1.7	6
844	Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis. Oncology Reviews, 0, 16, .	0.8	2
845	Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. The Cochrane Library, 2022, 2022, .	1.5	12
846	Epithelial ovarian cancer: Review article. Cancer Treatment and Research Communications, 2022, 33, 100629.	0.7	26
847	Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues. Clinical Proteomics, 2022, 19, .	1.1	2
849	The BUMPy road of peritoneal metastases in ovarian cancer. Diagnostic and Interventional Imaging, 2022, 103, 448-459.	1.8	5
850	Tumor Load Matters – the Peritoneal Cancer Index in Patients With High-grade Serous Ovarian Cancer. Anticancer Research, 2022, 42, 4825-4831.	0.5	0
851	Prognostic Significance of Clinical Factors Including BRCA Mutation in Epithelial Ovarian, Peritoneal, Fallopian Tube Cancer. Anticancer Research, 2022, 42, 4945-4954.	0.5	1
852	Treatment of Advanced-Stage Ovarian Cancer. , 2022, , 105-119.		0
853	Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan. Journal of Gynecologic Oncology, 2022, 34, .	1.0	2
854	18F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study. Frontiers in Oncology, 0, 12, .	1.3	3
855	Disruption of the Gut Microbiota Confers Cisplatin Resistance in Epithelial Ovarian Cancer. Cancer Research, 2022, 82, 4654-4669.	0.4	29
856	Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer. Gynecologic Oncology, 2022, 167, 417-422.	0.6	2

#	ARTICLE	IF	CITATIONS
857	Primary mucinous ovarian cancer: options for surgery and chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1455-1462.	1.2	7
858	Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by an Expert Group from Middle East and North Africa Region. <i>Current Women's Health Reviews</i> , 2022, 19, .	0.1	0
859	Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2022, 167, 547-556.	0.6	11
860	Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints. <i>Cancers</i> , 2022, 14, 5332.	1.7	5
862	Efficacy and safety of Gemogenovatucl-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
864	Epithelial ovarian cancer. , 2023, , 250-281.e8.		0
865	Transanal total mesorectal excision for primary rectovaginal carcinosarcoma: A case report and literature review. <i>Journal of Obstetrics and Gynaecology Research</i> , 2023, 49, 763-768.	0.6	0
866	Anastomotic Leak in Ovarian Cancer Cytoreduction Surgery: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 5464.	1.7	0
867	Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer. <i>Pharmaceutical Research</i> , 2023, 40, 123-144.	1.7	3
869	Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction. <i>Medicina (Lithuania)</i> , 2022, 58, 1611.	0.8	4
870	Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical) Tj ETQq0 0 0 rgBTLD Overlock 10 Tf 50 3		
871	Patterns of Treatment and Outcomes in Epithelial Ovarian Cancer: A Retrospective North Indian Single-Institution Experience. <i>JCO Global Oncology</i> , 2022, , .	0.8	3
872	Outcomes of Laparoscopic Optimal Interval Cytoreduction Surgery (LOICS) in Patients with Advanced Ovarian Cancers Having Low Burden Disease. <i>Indian Journal of Surgical Oncology</i> , 0, , .	0.3	0
873	Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. <i>Gynecologic Oncology</i> , 2023, 168, 68-75.	0.6	0
874	The 1st Indonesian Society Gynecologic Oncology Scientific Meeting (INASMEET), November 12th to November 13th, 2022. <i>Journal of Gynecologic Oncology</i> , 0, 34, .	1.0	0
875	Role of diagnostic laparoscopy in deciding primary treatment in advanced-stage ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 0, 34, .	1.0	1
876	Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 169, 55-63.	0.6	5
877	Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2023, 169, 41-46.	0.6	0

#	ARTICLE	IF	CITATIONS
879	Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 3791-3799.	0.5	1
880	Does the primary treatment sequence affect post-relapse survival in recurrent epithelial ovarian cancer? A real-world multicentre retrospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 70-78.	1.1	1
881	Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on chemotherapy response score and recurrence in high-grade serous ovarian cancer patients with advanced disease: A multicentre retrospective cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 5-13.	1.1	1
882	Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 50-56.	1.2	1
884	Transvaginal ultrasound-guided biopsy in patients with suspicious primary advanced tubo-ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2022-003890.	1.2	1
886	CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	2
887	Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes. <i>Cancers</i> , 2022, 14, 6010.	1.7	4
888	Neoadjuvant chemotherapy in patients with stage IVB uterine serous carcinoma: a Turkish multicentric study. <i>Journal of Obstetrics and Gynaecology</i> , 0, , .	0.4	1
889	Impact of consolidation chemotherapy after delayed complete surgery in advanced epithelial ovarian cancer: a propensity score analysis. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2022-003920.	1.2	0
890	Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumab. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 543-548.	1.2	1
891	Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art. <i>Przegląd Menopauzalny</i> , 2022, 21, 272-275.	0.6	2
892	Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary. <i>JCO Oncology Practice</i> , 0, , .	1.4	0
893	Diagnostic and Therapeutic Pathway of Advanced Ovarian Cancer with Peritoneal Metastases. <i>Cancers</i> , 2023, 15, 407.	1.7	2
894	Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level – A Memorial Sloan Kettering Cancer Center study. <i>Gynecologic Oncology</i> , 2023, 170, 46-53.	0.6	7
895	Development and Validation of 18F-FDG PET/CT-Based Models for Predicting Successful Complete Cytoreduction During Primary Cytoreductive Surgery for Advanced Ovarian cancer. <i>Clinical Nuclear Medicine</i> , 2023, 48, e51-e59.	0.7	2
897	Development of a prediction model for gross residual in high-grade serous ovarian cancer by combining preoperative assessments of abdominal and pelvic metastases and multiparametric MRI. <i>Academic Radiology</i> , 2023, 30, 1823-1831.	1.3	3
898	Honeycomb-like Structured Film, a Novel Therapeutic Device, Suppresses Tumor Growth in an In Vivo Ovarian Cancer Model. <i>Cancers</i> , 2023, 15, 237.	1.7	0
899	Imaging Recommendations for Diagnosis, Staging, and Management of Ovarian and Fallopian Tube Cancers. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.1	0

#	ARTICLE	IF	CITATIONS
901	Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8 tumor-infiltrating lymphocytes and patient prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 755-766.	1.4	3
902	A three protein signature fails to externally validate as a biomarker to predict surgical outcome in high-grade epithelial ovarian cancer. <i>PLoS ONE</i> , 2023, 18, e0281798.	1.1	1
903	Calculating surgical readmission rates in gynecologic oncology: The impact of patient factors. <i>Gynecologic Oncology</i> , 2023, 172, 115-120.	0.6	0
904	The past, present, and future of opioid prescribing: Perioperative opioid use in gynecologic oncology patients after laparotomy at a single institution from 2012 to 2021. <i>Gynecologic Oncology Reports</i> , 2023, 46, 101172.	0.3	0
905	Fallopian Tube Carcinoma. , 2022, , 357-361.		0
906	Epithelial Ovarian Cancer. , 2022, , 291-323.		1
907	The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma. <i>Journal of Gynecologic Oncology</i> , 2023, 34, .	1.0	2
908	Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial. <i>Gynecologic Oncology</i> , 2023, 170, 186-194.	0.6	3
909	Management of patients with advanced epithelial ovarian cancer: a European survey. <i>Archives of Gynecology and Obstetrics</i> , 0, , .	0.8	0
910	Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis. <i>Medicine (United States)</i> , 2023, 102, e32774.	0.4	3
911	Beyond post-operative readmissions: analysis of the impact of unplanned readmissions during primary treatment of advanced-stage epithelial ovarian cancer on long-term oncology outcome. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 741-748.	1.2	0
912	Yá³¼U Tá»•TIAŠN LÆ´á»¢NG Tá»ª CÃC Bá»†NH NHÃ,N UNG THÆ´ Blá»‚U MÃ” BUá»’NG TRá»”NG GIAI ÄOá”N III ÄÆ´á»¢C Äá»¢EU TRá»”S P HOÄ•TRá»”Š Bá»” TRá»¢ Tá”l Bá»†NH Vlá»†N K. <i>Y Hoc Viet Nam</i> , 2023, 523, .	0.0	0
913	Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
914	Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer. <i>Medicine (United States)</i> , 2023, 102, e33271.	0.4	0
915	Phases of clinical trials. , 2023, , 379-388.		0
916	Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2023, 172, 130-137.	0.6	5
917	Neoadjuvant chemotherapy induces an elevation of tumour apparent diffusion coefficient values in patients with ovarian cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
918	Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era”Is it time for a new paradigm shift? A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2023, 187, 77-86.	1.3	4

#	ARTICLE	IF	CITATIONS
919	Prognostic Role of Pathological Complete Response in Early Stage Epithelial Solid Tumors. <i>Cancer Control</i> , 2023, 30, .	0.7	1
921	Feasibility of extended cycles of neoadjuvant chemotherapy in patients with advanced ovarian cancer in terms of prognosis and surgical outcomes. <i>PLoS ONE</i> , 2023, 18, e0284753.	1.1	0
922	Olaparib and advanced ovarian cancer: Summary of the past and looking into the future. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
942	Diagnosis and Management of Epithelial Ovarian Cancer. , 2023, , 1-20.		0
967	Enhancing PFI Prediction with AGDS-MIL: A Graph-Based Dual Stream MIL Approach. <i>Lecture Notes in Computer Science</i> , 2023, , 550-562.	1.0	0
973	Low-Grade Serous Ovarian Carcinoma. , 2023, , 31-41.		0
974	Non-serous and Rare Histologies of Ovarian Cancer. , 2023, , 43-51.		0
975	Epithelial Ovarian Cancer: High Grade Serous. , 2023, , 15-30.		0
990	Diagnosis and Management of Epithelial Ovarian Cancer. , 2023, , 1069-1088.		0
1019	Case report: Minimally invasive primary debulking surgery for advanced stage epithelial ovarian cancer. <i>Frontiers in Oncology</i> , 0, 14, .	1.3	0
1025	Advances in the Medical Management of Ovarian Cancer. , 2023, , 345-396.		0
1027	Clear Cell Carcinoma of the Ovary. , 2023, , 457-478.		0
1028	Surgical Management of Ovarian Cancer. , 2023, , 235-250.		0